高血压继发左心室肥厚的分子遗传学研究
|
摘要
第一部分内皮型一氧化氮合酶基因与高血压继发左心室肥厚的关联性研究
研究背景
左心室肥厚(LVH)是心血管疾病发病率和死亡率的独立预测危险因素。目前已知年龄、性别、绝经、生活方式与糖尿病等均是LVH的重要危险因素。虽然高血压的主要并发症是LVH,但是高血压继发LVH的患者其LVH的程度与高血压病史的长短、血压水平及降压后肥厚逆转的程度并不呈比例,提示有高血压以外的因素参与心肌肥厚进程。研究表明,遗传因素对左心室重量的影响约占非血压因素的60%。内皮型一氧化氮合酶(eNOS)可催化L-精氨酸生成NO,NO/NOS途径参与心肌肥厚的病理、生理过程。在动物模型中,长期给予NOS抑制剂(L-NAME)或者NOS3-/-小鼠均会出现LVH、心肌纤维化和心功能异常;建立NOS3-/-小鼠主动脉弓缩窄(TAC)压力超负荷左心室肥厚的动物模型,向心脏内注射eNOS后可以缓解LVH以及由此导致的心功能异常。此外,eNOS还可以抑制心梗后小鼠的心肌肥厚,保护其心脏的功能。心衰病人心室肌中eNOS基因(NOS3)的表达是增加的。关于NOS3与高血压继发LVH的关联研究目前仅一篇报道,其结果表明NOS3基因多态性与左室肥厚相关联。但是这种关联在其他人群中尚未得到证实。
研究目的
本研究拟在中国人群中验证NOS3多态性与高血压继发左心室肥厚的关联。
对象和方法
本研究选择两个独立的高血压继发左室肥厚的病例和对照人群(2179和343人),采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)法研究eNOS基因的三个功能性多态性位点(-T786C/rs2070744、eNOS4a/b和+G894T/rs1799983)多态性与原发性高血压继发左室肥厚遗传易感因素的关系。所有入选者均进行心脏超声的检测。
研究结果
结果显示只有+G894T(Glu298Asp)位点与高血压继发左室肥厚的易感相关(第一个人群:OR=1.67,95%CI:1.19-2.36,P＜0.05;第二个人群:OR=1.41,95%CI:1.01-2.28,P＜0.05),并呈隐性遗传模式。在两个独立样本中,与携带G等位基因(GT+GG)的相比,携带TT基因型的患者的室间隔厚度、左室后壁厚度、左室重量指数和相对室壁厚度均增加(分别增加16.2%和11.7%、8.3%和7.1%、14.0%和25.1%、13.1%和16.2%)且均有统计学意义(P＜0.01)。
结论eNOS基因+G894T多态可能是高血压继发左室肥厚遗传易感性的标记之一。这为高血压继发左室肥厚遗传易感性提供了循证医学依据,同时也为在中国开展+G894T多态性与高血压继发左室肥厚关系的研究提供了基础。
第二部分二甲基精氨酸-二甲胺水解酶基因与高血压继发左心室肥厚的关联性研究
研究背景
左心室肥厚(LVH)是心血管疾病发病率和死亡率的独立预测危险因素。目前已知年龄、性别、绝经、生活方式与糖尿病等均是LVH的重要危险因素。虽然高血压的主要并发症是LVH,但是高血压继发LVH的患者其LVH的程度与高血压病史的长短、血压水平及降压后肥厚逆转的程度并不呈比例,提示有高血压以外的因素参与心肌肥厚进程。研究表明,遗传因素对左心室重量的影响约占非血压因素的60%。非对称性二甲基精氨酸(ADMA)是一种内源性一氧化氮和酶(NOS)的抑制剂,研究显示ADMA与左心质量呈显著正相关,与射血分数呈显著负相关。NO可以调节心肌的生长,ADMA/NO途径对于心肌肥厚的病理过程是重要的。二甲基精氨酸-二甲胺水解酶(DDAH2)存在于表达内皮型一氧化氮合酶的组织中,可以代谢大部分的ADMA。关于DDAH2与高血压继发LVH的关联研究目前还没有相关报道。
研究目的
本研究拟在大样本人群中研究DDAH2多态性与高血压左心室肥厚的关联性。
对象和方法
研究对象为河南信阳高血压基地收集的2,274例高血压患者,其中包括1,135例高血压伴LVH患者,1,139例高血压不伴有LVH患者及767例健康对照者。所有入选者均进行心脏超声的检测。使用单倍体型-tagging-SNPs的方法,研究DDAH2基因tagSNPs与原发性高血压继发左室肥厚遗传易感因素的关系。并进一步运用萤光素酶分析研究DDAH2变异对基因表达的影响效应。
研究结果
本研究发现DDAH2只有一个tag-SNP,是位于启动子区的变异-449C/G(rs805305),其与其他SNPs(rs70791 6,rs805304)完全连锁。对于-449C/G变异,与携带GG基因型的患者相比,携带C等位基因(GC+CC)的高血压左室肥厚患者的左室重量指数(62.0±1 5.7g/m~(2.7)vs.59.9±13.1g/m~(2.7),P＜0.05)、左室后壁厚度(62.0±15.7g/m~(2.7)vs.59.9±13.1g/m~(2.7),P＜0.05)以及相对室壁厚度(47.9±12.9%vs.46.0±11.0%,P＜0.01)均增加。此外,-449位携带C等位基因(GC+CC)增加高血压左心室肥厚的易感度(OR=1.26,95%CI:1.03-1.53,P＜0.01)。含有SNP-449C的DAH2启动子区明显降低转录活性(49.5%)。
结论
DDAH2-449C/G变异可能是高血压继发左室肥厚遗传易感性的基因标记之一。这为高血压继发左室肥厚遗传易感性提供了循证医学依据,同时也为在世界上开展-449C/G多态性与高血压继发左室肥厚关系的研究提供了基础。
Background
Left ventricular hypertrophy(LVH)is a strong,independent risk factor for cardiovascular morbidity and all-cause mortality.The following factors,age,male,gender, postmenopausal status in women,life style and diabetes,have been known to contribute to the development of LVH.Although hypertension is a major cause of LVH,the degree of LVH does not parallel the level of blood pressure,the duration of hypertension,or reversal of hypertensive LVH by pharmacological treatments.Indeed,genetic factors account for 60%of blood pressure-independent cardiac mass variances,suggesting the important role played by genetic factors in the development of LVH in essential hypertension.Endothelial nitric oxide synthase(eNOS)plays a critical role in the development of ventricular remodeling and cardiac hypertrophy.The purpose of the study was to determine whether three common variants in the eNOS gene(NOS3)are associated with risk of LVH in patients with essential hypertension.In animal models, long-term systemic inhibition of NO production with the NOS inhibitor L-NAME or NOS3-deficient mice have been shown to induce greater LVH,fibrosis and dysfunction, especially concentric LVH.Restoration of eNOS in the heart of NOS3-deficient mice has been shown to attenuate LVH and dysfunction in transverse ascending aorta constriction (TAC)model,and also inhibits hypertrophy in the remote myocardium and preserves cardiac function after myocardial infarction.Furthermore,the expression of NOS3 has been shown to be increased in the ventricular myocardium of failing human hearts, suggesting that the endothelial NO/NOS pathway has an important role in left ventricular remodeling and LVH.
Objectives
The purpose of the study was to determine whether three common variants in the eNOS gene(NOS3)are associated with risk of left ventricular hypertrophy(LVH)in patients with essential hypertension.
Methods
Three NOS3 genetic variants,-T786C(rs2070744),eNOS4a/b and +G894T(rs1799983) were genotyped in two independent case-control studies:the first study consisted of 1,061 hypertensive patients with LVH and 1,118 hypertensive patients without LVH,and the second sample consisted of 120 patients with LVH and 223 patients without LVH. Echocardiographic measurements were obtained in all the hypertensive patients.
Results
Only the+G894T(Glu298Asp)variant of NOS3 was associated with higher risk of LVH (OR=1.67,95%CI:1.19-2.36,P＜0.01)in the first population;and replicated in the second population(OR=1.41,95%CI:1.01-2.28,P＜0.05)in a recessive model. Compared with carriers of the G allele(GT+GG),patients carrying the TT genotype had increased septal wall thickness(16.2%,P＜0.01;11.7%,P＜0.01,respectively);left ventricular posterior wall thickness(8.3%,P＜0.01;7.1%,P＜0.01,respectively);left ventricular mass index(14.0%,P＜0.01;25.1%,P＜0.01,respectively)and relative wall thickness(13.1%,P＜0.01;16.2%,P＜0.01,respectively)in the first and second populations.
Conclusions
Our results support that homozygosity for +G894T(Glu298Asp)in NOS3 is a genetic risk factor for the development of LVH in patients with hypertension.
Background
Left ventricular hypertrophy(LVH)is a strong,independent risk factor for cardiovascular morbidity and all-cause mortality.The following factors,age,male,gender, postmenopausal status in women,life style and diabetes,have been known to contribute to the development of LVH.Although hypertension is a major cause of LVH,the degree of LVH does not parallel the level of blood pressure,the duration of hypertension,or reversal of hypertensive LVH by pharmacological treatments.Indeed,genetic factors account for 60%of blood pressure-independent cardiac mass variances,suggesting the important role played by genetic factors in the development of LVH in essential hypertension.Since nitric oxide(NO)modulates the growth of the myocardium, Asymmetric dimethylarginine(ADMA),an endogenous inhibitor of nitric oxide synthase (NOS)has been shown to be significantly related to left-ventricular mass and inversely related to ejection fraction.The bulk of ADMA is degraded by an enzyme named dimethylarginine dimethylaminohydrolase 2(DDAH2),which is found in tissues that express endothelial isoforms of nitric oxide synthase.ADMA/NO pathway is important for the pathogenesis of LVH.
Objectives
The purpose of the study was to determine whether the common variant in the dimethylarginine dimethylaminohydrolase 2(DDAH2)gene is associated with risk of left ventricular hypertrophy(LVH)in patients with essential hypertension.
Methods
The case-control study consisted of 1,135 hypertensive patients with LVH and 1,139 hypertensive patients without LVH,as well as 767 control subjects.We used a haplotype-tagging single nucleotide polymorphisms(SNPs)approach to identify tag SNPs in DDAH2.The tag SNPs were genotyped in case-control study.The effect of DDAH2 variants on gene expression was studiedby use of luciferase reporter assays.
Results
A promoter variant-449C/G(rs805305)was identified and found to be the only tag-SNP in completely linkage disequilibrium with other SNPs(rs707916,rs805304)in the region containing DDAH2.Compared with the carriers of the GG genotype,the hypertensive patients with LVH carrying the C allele(GC+CC)had an increase in the LV mass index (62.0±15.7 g/m2.7 vs.59.9±13.1 g/m2.7,P＜0.05),posterior wall thickness(12.1±2.9 mm vs.11.4±1.9 mm,P＜0.01),and relative wall thickness(47.9±12.9%vs.46.0±11.0%, P＜0.01).In addition,the C allele(GC±CC)of the -449 locus was associated with higher risk ofLVH(OR=1.26,95%CI:1.03-1.53,P＜0.01)in the study.The SNP-449C-bearing DDAH2 promoter exhibited 49.5%of lower transcription activity than the SNP-449G-bearing promoter.
Conclusions
Our results support that the DDAH2 common variant is a genetic risk factor for the development of LVH in patients with essential hypertension.
研究背景
左心室肥厚(LVH)是心血管疾病发病率和死亡率的独立预测危险因素。目前已知年龄、性别、绝经、生活方式与糖尿病等均是LVH的重要危险因素。虽然高血压的主要并发症是LVH,但是高血压继发LVH的患者其LVH的程度与高血压病史的长短、血压水平及降压后肥厚逆转的程度并不呈比例,提示有高血压以外的因素参与心肌肥厚进程。研究表明,遗传因素对左心室重量的影响约占非血压因素的60%。内皮型一氧化氮合酶(eNOS)可催化L-精氨酸生成NO,NO/NOS途径参与心肌肥厚的病理、生理过程。在动物模型中,长期给予NOS抑制剂(L-NAME)或者NOS3-/-小鼠均会出现LVH、心肌纤维化和心功能异常;建立NOS3-/-小鼠主动脉弓缩窄(TAC)压力超负荷左心室肥厚的动物模型,向心脏内注射eNOS后可以缓解LVH以及由此导致的心功能异常。此外,eNOS还可以抑制心梗后小鼠的心肌肥厚,保护其心脏的功能。心衰病人心室肌中eNOS基因(NOS3)的表达是增加的。关于NOS3与高血压继发LVH的关联研究目前仅一篇报道,其结果表明NOS3基因多态性与左室肥厚相关联。但是这种关联在其他人群中尚未得到证实。
研究目的
本研究拟在中国人群中验证NOS3多态性与高血压继发左心室肥厚的关联。
对象和方法
本研究选择两个独立的高血压继发左室肥厚的病例和对照人群(2179和343人),采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)法研究eNOS基因的三个功能性多态性位点(-T786C/rs2070744、eNOS4a/b和+G894T/rs1799983)多态性与原发性高血压继发左室肥厚遗传易感因素的关系。所有入选者均进行心脏超声的检测。
研究结果
结果显示只有+G894T(Glu298Asp)位点与高血压继发左室肥厚的易感相关(第一个人群:OR=1.67,95%CI:1.19-2.36,P＜0.05;第二个人群:OR=1.41,95%CI:1.01-2.28,P＜0.05),并呈隐性遗传模式。在两个独立样本中,与携带G等位基因(GT+GG)的相比,携带TT基因型的患者的室间隔厚度、左室后壁厚度、左室重量指数和相对室壁厚度均增加(分别增加16.2%和11.7%、8.3%和7.1%、14.0%和25.1%、13.1%和16.2%)且均有统计学意义(P＜0.01)。
结论eNOS基因+G894T多态可能是高血压继发左室肥厚遗传易感性的标记之一。这为高血压继发左室肥厚遗传易感性提供了循证医学依据,同时也为在中国开展+G894T多态性与高血压继发左室肥厚关系的研究提供了基础。
第二部分二甲基精氨酸-二甲胺水解酶基因与高血压继发左心室肥厚的关联性研究
研究背景
左心室肥厚(LVH)是心血管疾病发病率和死亡率的独立预测危险因素。目前已知年龄、性别、绝经、生活方式与糖尿病等均是LVH的重要危险因素。虽然高血压的主要并发症是LVH,但是高血压继发LVH的患者其LVH的程度与高血压病史的长短、血压水平及降压后肥厚逆转的程度并不呈比例,提示有高血压以外的因素参与心肌肥厚进程。研究表明,遗传因素对左心室重量的影响约占非血压因素的60%。非对称性二甲基精氨酸(ADMA)是一种内源性一氧化氮和酶(NOS)的抑制剂,研究显示ADMA与左心质量呈显著正相关,与射血分数呈显著负相关。NO可以调节心肌的生长,ADMA/NO途径对于心肌肥厚的病理过程是重要的。二甲基精氨酸-二甲胺水解酶(DDAH2)存在于表达内皮型一氧化氮合酶的组织中,可以代谢大部分的ADMA。关于DDAH2与高血压继发LVH的关联研究目前还没有相关报道。
研究目的
本研究拟在大样本人群中研究DDAH2多态性与高血压左心室肥厚的关联性。
对象和方法
研究对象为河南信阳高血压基地收集的2,274例高血压患者,其中包括1,135例高血压伴LVH患者,1,139例高血压不伴有LVH患者及767例健康对照者。所有入选者均进行心脏超声的检测。使用单倍体型-tagging-SNPs的方法,研究DDAH2基因tagSNPs与原发性高血压继发左室肥厚遗传易感因素的关系。并进一步运用萤光素酶分析研究DDAH2变异对基因表达的影响效应。
研究结果
本研究发现DDAH2只有一个tag-SNP,是位于启动子区的变异-449C/G(rs805305),其与其他SNPs(rs70791 6,rs805304)完全连锁。对于-449C/G变异,与携带GG基因型的患者相比,携带C等位基因(GC+CC)的高血压左室肥厚患者的左室重量指数(62.0±1 5.7g/m~(2.7)vs.59.9±13.1g/m~(2.7),P＜0.05)、左室后壁厚度(62.0±15.7g/m~(2.7)vs.59.9±13.1g/m~(2.7),P＜0.05)以及相对室壁厚度(47.9±12.9%vs.46.0±11.0%,P＜0.01)均增加。此外,-449位携带C等位基因(GC+CC)增加高血压左心室肥厚的易感度(OR=1.26,95%CI:1.03-1.53,P＜0.01)。含有SNP-449C的DAH2启动子区明显降低转录活性(49.5%)。
结论
DDAH2-449C/G变异可能是高血压继发左室肥厚遗传易感性的基因标记之一。这为高血压继发左室肥厚遗传易感性提供了循证医学依据,同时也为在世界上开展-449C/G多态性与高血压继发左室肥厚关系的研究提供了基础。
Background
Left ventricular hypertrophy(LVH)is a strong,independent risk factor for cardiovascular morbidity and all-cause mortality.The following factors,age,male,gender, postmenopausal status in women,life style and diabetes,have been known to contribute to the development of LVH.Although hypertension is a major cause of LVH,the degree of LVH does not parallel the level of blood pressure,the duration of hypertension,or reversal of hypertensive LVH by pharmacological treatments.Indeed,genetic factors account for 60%of blood pressure-independent cardiac mass variances,suggesting the important role played by genetic factors in the development of LVH in essential hypertension.Endothelial nitric oxide synthase(eNOS)plays a critical role in the development of ventricular remodeling and cardiac hypertrophy.The purpose of the study was to determine whether three common variants in the eNOS gene(NOS3)are associated with risk of LVH in patients with essential hypertension.In animal models, long-term systemic inhibition of NO production with the NOS inhibitor L-NAME or NOS3-deficient mice have been shown to induce greater LVH,fibrosis and dysfunction, especially concentric LVH.Restoration of eNOS in the heart of NOS3-deficient mice has been shown to attenuate LVH and dysfunction in transverse ascending aorta constriction (TAC)model,and also inhibits hypertrophy in the remote myocardium and preserves cardiac function after myocardial infarction.Furthermore,the expression of NOS3 has been shown to be increased in the ventricular myocardium of failing human hearts, suggesting that the endothelial NO/NOS pathway has an important role in left ventricular remodeling and LVH.
Objectives
The purpose of the study was to determine whether three common variants in the eNOS gene(NOS3)are associated with risk of left ventricular hypertrophy(LVH)in patients with essential hypertension.
Methods
Three NOS3 genetic variants,-T786C(rs2070744),eNOS4a/b and +G894T(rs1799983) were genotyped in two independent case-control studies:the first study consisted of 1,061 hypertensive patients with LVH and 1,118 hypertensive patients without LVH,and the second sample consisted of 120 patients with LVH and 223 patients without LVH. Echocardiographic measurements were obtained in all the hypertensive patients.
Results
Only the+G894T(Glu298Asp)variant of NOS3 was associated with higher risk of LVH (OR=1.67,95%CI:1.19-2.36,P＜0.01)in the first population;and replicated in the second population(OR=1.41,95%CI:1.01-2.28,P＜0.05)in a recessive model. Compared with carriers of the G allele(GT+GG),patients carrying the TT genotype had increased septal wall thickness(16.2%,P＜0.01;11.7%,P＜0.01,respectively);left ventricular posterior wall thickness(8.3%,P＜0.01;7.1%,P＜0.01,respectively);left ventricular mass index(14.0%,P＜0.01;25.1%,P＜0.01,respectively)and relative wall thickness(13.1%,P＜0.01;16.2%,P＜0.01,respectively)in the first and second populations.
Conclusions
Our results support that homozygosity for +G894T(Glu298Asp)in NOS3 is a genetic risk factor for the development of LVH in patients with hypertension.
Background
Left ventricular hypertrophy(LVH)is a strong,independent risk factor for cardiovascular morbidity and all-cause mortality.The following factors,age,male,gender, postmenopausal status in women,life style and diabetes,have been known to contribute to the development of LVH.Although hypertension is a major cause of LVH,the degree of LVH does not parallel the level of blood pressure,the duration of hypertension,or reversal of hypertensive LVH by pharmacological treatments.Indeed,genetic factors account for 60%of blood pressure-independent cardiac mass variances,suggesting the important role played by genetic factors in the development of LVH in essential hypertension.Since nitric oxide(NO)modulates the growth of the myocardium, Asymmetric dimethylarginine(ADMA),an endogenous inhibitor of nitric oxide synthase (NOS)has been shown to be significantly related to left-ventricular mass and inversely related to ejection fraction.The bulk of ADMA is degraded by an enzyme named dimethylarginine dimethylaminohydrolase 2(DDAH2),which is found in tissues that express endothelial isoforms of nitric oxide synthase.ADMA/NO pathway is important for the pathogenesis of LVH.
Objectives
The purpose of the study was to determine whether the common variant in the dimethylarginine dimethylaminohydrolase 2(DDAH2)gene is associated with risk of left ventricular hypertrophy(LVH)in patients with essential hypertension.
Methods
The case-control study consisted of 1,135 hypertensive patients with LVH and 1,139 hypertensive patients without LVH,as well as 767 control subjects.We used a haplotype-tagging single nucleotide polymorphisms(SNPs)approach to identify tag SNPs in DDAH2.The tag SNPs were genotyped in case-control study.The effect of DDAH2 variants on gene expression was studiedby use of luciferase reporter assays.
Results
A promoter variant-449C/G(rs805305)was identified and found to be the only tag-SNP in completely linkage disequilibrium with other SNPs(rs707916,rs805304)in the region containing DDAH2.Compared with the carriers of the GG genotype,the hypertensive patients with LVH carrying the C allele(GC+CC)had an increase in the LV mass index (62.0±15.7 g/m2.7 vs.59.9±13.1 g/m2.7,P＜0.05),posterior wall thickness(12.1±2.9 mm vs.11.4±1.9 mm,P＜0.01),and relative wall thickness(47.9±12.9%vs.46.0±11.0%, P＜0.01).In addition,the C allele(GC±CC)of the -449 locus was associated with higher risk ofLVH(OR=1.26,95%CI:1.03-1.53,P＜0.01)in the study.The SNP-449C-bearing DDAH2 promoter exhibited 49.5%of lower transcription activity than the SNP-449G-bearing promoter.
Conclusions
Our results support that the DDAH2 common variant is a genetic risk factor for the development of LVH in patients with essential hypertension.
引文
[1]Levy D,Garrison RJ,Savage DD,et al.Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.N Engl J Med.May 31 1990,322(22):1561-1566.
[2]Vakili BA,Okin PM,Devereux RB.Prognostic implications of left ventricular hypertrophy.Am Heart J.Mar 2001,141(3):334-341.
[3]Di Tullio MR,Zwas DR,Sacco RL,et al.Left ventricular mass and geometry and the risk of ischemic stroke.Stroke.Oct 2003,34(10):2380-2384.
[4]Verdecchia P,Porcellati C,Reboldi G,et al.Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.Circulation.Oct 23 2001,104(17):2039-2044.
[5]Schmieder RE,Martus P,Klingbeil A.Reversal of left ventricular hypertrophy in essential hypertension.A meta-analysis of randomized double-blind studies.Jama.May 15 1996,275(19):1507-1513.
[6]Galderisi M,Anderson KM,Wilson PW,et al.Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy(the Framingham Heart Study).Am J Cardiol.Jul 1 1991,68(1):85-89.
[7]Ganau A,Devereux RB,Pickering TG,et al.Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension.Circulation.Jan 1990,81(1):25-36.
[8]Post WS,Larson MG,Myers RH,et al.Heritability of left ventricular mass:the Framingham Heart Study.Hypertension.Nov 1997,30(5):1025-1028.
[9]Tanase H,Yamori Y,Hansen CT,et al.Heart size in inbred strains of rats.Part 1.Genetic determination of the development of cardiovascular enlargement in rats.Hypertension.Nov-Dec 1982,4(6):864-872.
[10]Huss JM,Kelly DP.Nuclear receptor signaling and cardiac energetics.Circ Res.2004,95:568-578.
[1 l]F(?)rstermann U,Boissel JP,Kleinert H.Expressional control of the 'constitutive' isoforms of nitric oxide synthase(NOS I and NOS III).FASEB J.1998 Jul,12(10):773-790.
[12]F(?)rstermann U,Closs El,Pollock JS,et al.Nitric oxide synthase isozymes.Characterization,purification,molecular cloning,and functions.Hypertension.1994 Jun,23(6 Pt 2):1121-1131.
[13]F(?)rstermann U,Pollock JS,Schmidt HH,et al.Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells.Proc Natl Acad Sci U S A.1991 Mar 1,88(5):1788-1792.
[14]Sladek T,Gerova M,Znojil V,et al.Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase.Physiol Res 1996,45:335-338.
[15]Ichinose F,Bloch KD,Wu JC,et al.Pressure overload induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency.Am J Physiol Heart Circ Physiol.2004,286(3):H1070-H1075.
[16]Buys ES,Raher MJ,Blake SL,et al.Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload.Am J Physiol Heart Circ Physiol.2007,293:H620-H627.
[17]Janssens S,Pokreisz P,Schoonjans L,et al.Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.Circ.Res.2004,94:1256-1262.
[18]Stein B,Eschenhagen T,R(?)diger J,et al.Increased expression of constitutive nitric oxide synthase III,but not inducible nitric oxide synthase II,in human heart failure.J.Am.Coll.Cardiol.1998,32:1179-1186.
[19]Nakayama M,Yasue H,Yoshimura M,et al.-T786C mutation in the 5'-flanking region of the endothdial nitric oxide symhase gene is associated with myocardial infarction,especially without coronary organic stenosis.Am J Cardiol.2000,86(6):628-634.
[20]Pulkkinen A,Viitanen L,Kareinen A,et al.Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease.J Mol Med.2000,78(7):372-379.
[21]Btiyamoto Y,Saito Y,Kajiym N,et al.Hypertension.1998,32(1):3-8.
[22]Uwabo J,Soma M,Nakayama T,et al.Am J Hypertens.1998,11(1):125-128.
[23]Whitworth JA.2003 World Health Organization(WHO)/International Society of Hypertension(ISH) statement on management of hypertension.J Hypertens.Nov 2003,21(11):1983-1992.
[24]Tajik AJ,Seward JB,Hagler DJ,et al.Two-dimensional real-time ultrasonic imaging of the heart and great vessels.Mayo Clin Proc.1978,53:271-303.
[25]Sahn DJ,DeMaria A,Kisslo J,et al.Recommendations regarding quantitation in M-mode echocardiography:results of a survey of echocardiographic measurements. Circulation.1978,58:1072-1083.
[26]Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy finding.Am J Cardiol.1986,57:450-458.
[27]De Simone G,Devereux RB,Daniels SR,et al.Effect of growth on variability of left ventricular mass:assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk.J Am Coll Cardiol.1995,25:1056-1062.
[28]Ganau A,Devereux RB,Roman MJ,et al.Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.J Am Coll Cardiol.1992,19:1550-1558.
[29]Leadon SA,Cerutti PA.A rapid and mild procedure of the isolation of DNA from mammalian cells.Anal Biochem.1982,120:282-288.
[30]Committee E.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.Jul 1997,20(7):1183-1197.
[31]Cockcroft DW,Gauh MH.Prediction of creatinine clearance from serum creatinine.Nephron.1976,16:31-41.
[32]Kato N,Sugiyama T,Morita H,et al.Genetic analysis of the atrial natriuretic peptide gene in essential hypertension.Clin Sci.2000,98:251-258.
[33]Garcia-Cardena G,Martasek P,Masters BS,et al.Dissecting the interaction between nitric oxide synthase(NOS) and caveolin.Functional significance of the NOS caveolin binding domain in vivo.J.Biol.Chem.1997,272:25437-25440.
[34]Shaul PW,Anderson RG.Role of plasmalemmal caveolae in signal transduction.Am.J.Physiol.1998,275:L843-L851.
[35]Govers R,Rabelink TJ.Cellular regulation of endothelial nitric oxide synthase.Am.J.Physiol.2001,280:F193-F206.
[36]Nakayama M,Yasue H,Yoshimura M,et al.T-786＞C mutation in the 5'-flanking region of endothelial nitric oxide synthase gene is associated with coronary spasm.Circulation.1999,99:2864-2870.
[37]Wang XL,Sim AS,Wang MX,et al.Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity.FEBS Lett.2000,471:45-50.
[38]Tesauro M,Thompson WC,Rogliani P,et al.Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary disease:cleavage of proteins with aspartate vs.Glutamate at position 298.Proc Natl Acad Sci USA.2000,97:2832-2835.
[39]Ahmadi KR,Weale ME,Xue ZY,et al.A single-nucleotide polymorphism tagging set for human drug metabolism and transport.Nat.Genet.2005,37:84-89.
[40]Fairchild TA,Fulton D,Fontana JT,et al.Acidic hydrolysis as a mechanism for the cleavage of the glu(298) asp variant of human endothelial nitric-oxide synthase.J.Biol.Chem.2001,276:26674-26679.
[41]McDonald DM,Alp NJ,Channon KM.Functional comparison of the endothelial nitric oxide synthase glu298asp polymorphic variants in human endothelial cells.Pharmacogenetics.2004,14:831-839.
[42]Lapu-Bula R,Quarshie A,Lyn D,et al.The 894T allele of endothelial nitric oxide synthase gene is related to left ventricular mass in African Americans with high-normal blood pressure.J.Natl.Med.Assoc.2005,97:197-205.
[43]Minushkina LO,Zate(?)shchikov DA,ZateTshchikova AA,et al.NOS3 gene polymorphism and left ventricular hypertrophy in patients with essential hypertension.Kardiologiia.2002,42:30-34.
[44]01cay A,Ekmekci CG,Ozbek U,et al.Negative association of endothelial nitric oxide gene polymorphism with hypertension in Turkish patients:effect of eNOS polymorphism on left ventricular hypertrophy.Cardiovasc.Ultrasound.2006,4:33.
[1]Kannel WB.Prevalence and natural history of electrocardiographic left ventricular hypertrophy.Am J Med.1983,3:4-11.
[2]Lorell BH,Carabello BA.Left ventricular hypertrophy:pathogenesis,detection,and prognosis.Circulation.2000,102:470-479.
[3]Hunter J J,Chien KR.Signaling pathways for cardiac hypertrophy and failure.N Engl J Med.1999,341:1276-1283.
[4]Wollert KC,Drexler H.Regulation of cardiac remodeling by nitric oxide:focus on cardiac myocite hypertrophy and apoptosis.Heart Fail Rev.2002,7:317-325.
[5]Kempf T,Wollert KC.Nitric oxide and the enigma of cardiac hypertrophy.Bioessays.2004,6:608-615.
[6]Russell B,Motlagh D,Ashley WW.Form follows function:how muscle shape is regulated by work.J Appl Physiol.2000,88:1127-1132.
[7]Pereira FEL.Hipertrofia cardiaca:aspectos morfologicos e patogeneticos.In Vassale DV,Lima EG(eds).Contratilidade miocardica:aspectos basicos e clinicos.Sao Paulo:BYK,1993,p13-28.
[8]Ozaki M,Kawashima S,Yamashita T,Hirase T,Ohashi Y,Inoue N,et al.Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion.Circ J.2002,66:851-856.
[9]Morgan HE,Gordon EE,Kira Y,Chua BHL,Russo LA,Peterson CI,et al.Biochemical mechanisms of cardiac hypertrophy.Ann Rev Physiol.1987,49:533-543.
[10]Von Harsdorf R,Kang RE,Fullerton M,Woodcock EA.Myocardial stretch stimulates phosphatidyl-inositol turnover.Circ Res.1989,65:494-501.
[11]Sussman A,Mcculloch A,Borg TK.Dance band on the titanic:biomechanical signaling in cardiac hypertrophy.Circ Res.2002,91:888-898.
[12]Burridge K,Chrzanowska-Wodnicka M.Focal adhesions,contractility,and signaling.Annu Rev Cell Dev Biol.1996,12:463-519.
[13]Dash R,Schmidt AG,Pathak A,Gerst MJ,Biniakiewicz D,Kadambi VJ,et al.Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy.Cardiovasc Res.2003,57:704-714.
[14]Campos LA,Iliescu R,Fontes M,Schlegel WP,Bader M,Baltatu OC.Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.Am J Physiol Heart Circ Physiol.2006,291(5):H2371-2376.
[15]Shubeita HE,Martinson EA,Van Bilsen M,Chien KR,Brow JH.Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by protein kinase C in neonatal rat ventricular myocytes.Proc Natl Acad Sci USA.1992,89:1305-1309.
[I6]Lindpaintner K,Ganten D.The cardiac rennin-angiotensin system:an appraisal of present experimental and clinical evidence.Circ Res.1991,68(1):905-921.
[17]Shirai H,Takahashi K,Katada T,Inagami T.Mapping of G protein coupling sites of the angiotensin II type 1 receptor.Hypertension.1995,25:726-730.
[18]Bernstein KE,Ali MS,Sayeski PP,Semeniuk D,Marrero MB.New insights into the cellular signaling of seven transmembrane receptors:the role of tyrosine phosphorylation.Lab Invest.1998,78:3-7.
[19]Mukoyama M,Nakajima M,Horiuchi M,Sasamura H,Pratt RE,Dzau VJ.Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.J Biol Chem.1993,268(33):24539-24542.
[20]Senbonmatsu T,Ichihara S,Price E,Gaffney FA,Inagami T.Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload.J Clin Invest.2000,106:R25-R29.
[21]Harada K,Komuro I,Shiojima I,Hayashi D,Kudoh S,Mizuno T,et al.Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice.Circulation.1998,97:1952-1959.
[22]Saltiel AR,Kahn CR.Insulin signalling and the regulation of glucose and lipid metabolism.Nature.2001,414:799-806.
[23]Velloso LA,Carvalho CR,Rojas FA,Folli F,Saad MJ.Insulin signalling in heart involves insulin receptor substrates-1 and-2,activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway.Cardiovasc Res.1998,40:96-102.
[24]Araujo EP,De Souza CT,Gasparetti AL,Ueno M,Boschero AC,Saad MJ,et al.Short-term in vivo inhibition of insulin receptor substrate-1 expression leads to insulin resistance,hyperinsulinemia,and increased adiposity.Endocrinology.2005,146:1428-1437.
[25]Zecchin HG,Carvalheira JBC,Saad MJA.Resistencia a insulina,diabetes e hipertensao:bases fisiopatologicas.Rev Bras Hipertens.2004,11(2):124-127.
[26]Gao F,Gao E,Yue TL,Ohlstein EH,Lopez BL,Christopher TA,et al.Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemiareperfusion:the roles of PI3-kinase,Akt,and endothelial nitric oxide synthase phosphorylation.Circulation.2002,105(12):1497-1502.
[27]Sykiotis GP,Papavassiliou AG.Serine phosphorylation of insulin receptor substrate-1:a novel target for the reversal of insulin resistance.Mol Endocrinol.2001,15:1864-1869.
[28]Brownsey RW,Boone AN,Allard MF.Actions of insulin on the mammalian heart:metabolism,pathology and biochemical mechanisms.Cardiovasc Res.1997,34:3-24.
[29]Samuelsson AM,Bollano E,Mobini R,Larsson BM,Omerovic E,Fu M,et al. Hyperinsulinemia:effect on cardiac mass/function,angiotensin II receptor expression,and insulin signaling pathways.Am J Physiol Heart Circ Physiol.2006,291:H787-H796.
[30]Lang D,Mosfer SI,Shakesby A,Donaldson F,Lewis MJ.Coronary microvascular endothelial cell redox state in left ventricular hypertrophy:the role of angiotensin II.Circ Res.2000,86:463-469.
[31]Sato K,Komaru T,Shioiri H,Takeda S,Takahashi K,Kanatsuka H,et al.Hypercholesterolemia impairs transduction of vasodilator signals derived from ischemic myocardium:myocardium-microvessel cross-talk.Arterioscler Thromb Vasc Biol.2004,24(11):2034-2039.
[32]Aikawa R,Nagai T,Tanaka M,Zou Y,Ishihara T,Takano H,et al.Reactive oxygen species in mechanical stress-induced cardiac hypertrophy.Biochem Biophys Res Commun.2001,289:901-907.
[33]Yao EH,Yu Y,Fukuda N.Oxidative stress on progenitor and stem cells in cardiovascular diseases.Curr Pharm Biotechnol.2006,7:101-108.
[34]Genda S,Miura T,Miki T,Ichikawa Y,Shimamoto K.K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia.J Am Coll Cardiol.2002,40(7):1339-1346.
[35]Lee TM,Lin MS,Chou TF,Tasai CH,Chang NC.Effect of pravastatin on left ventricular mass by activation of myocardial KATP channels in hypercholesterolemic rabbits.Atherosclerosis.2004,176:273-278.
[36]Lee TM,Lin SM,Chou TF,Chang NC.Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits.Am J Physiol Heart Circ Physiol.2005,288:H1352-H1358.
[37]Sugden P.H.Signaling pathways activated by vasoactive peptides in the cardiac myocytes and their role in the myocardial pathologies.J Card Fail.2002,8(6):S359-369.
[38]Vishnevetsky D,Kiyanista VA,Gandhi PJ.CD40 ligand:a novel target in the fight against cardiovascular disease.Ann Pharmacother.2004,38(9):1500-1508.
[39]Gelbmann CM,Leeb SN,Vogl D,Maendel M,Herfarth H,Scholmerich J,et al.Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts.Gut.2003,52(10):1448-1456.
[40]Vellaichamy E,Sommana NK,Pandey KN.Reduced cGMP signaling activates NF-kappaB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A. Biochem Biophys Res Commun.2005,327(1):106-111.
[41]Hansson GK.Mechanisms of disease:inflammation,atherosclerosis,and coronary artery disease.N Engl J Med.2005,352:1685-1695.
[42]Peng J,Gurantz D,Tran V,Cowling RT,Greenberg BH.Tumor necrosis factor-alpha-induced ATI receptor upregulation enhances angiotensina II-mediated cardiac fibroblast responses that favor fibrosis.Circ Res.2002,91:1119-1126.
[43]Bubikat A,De Windt LJ,Zetsche B,Fabritz L,Sickler H,Eckardt D,et al.Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice.J Biol Chem.2005,280(22):21594-21599.
[44]Barouch LA,Cappola TP,Harrison RW,Crone JK,Rodriguez ER,Burnett AL,et al.Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice.J Mol Cell Cardiol.2003,35:637-644.
[45]Fiedler B,Wollert KC.Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NF AT cascade in cardiac myocytes.Cardiovasc Res.2004,63(3):450-457.
[46]Cheng TH,Shih NL,Chen SY,Lin JW,Chen YL,Chen CH,et al.Nitric oxide inhibits endothel in-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation.Mol Pharmacol.2005,68(4):1183-1192.
[47]Bush PK,Bartkova J,Strom CC,Wulf-Andersen L,Hinrichsen R,Christoffersen TE,et al.Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro.Cardiovasc Res.2002,56:64-75.
[48]Massion PB,Feron O,Dessy C,Balligand JL.Nitric oxide and cardiac function:ten years after,and continuing.Circ Res.2003,93(5):388-398.
[49]Wollert KC,Fiedler B,Gambaryan S,Smolenski A,Heineke J,Butt E,et al.Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes.Hypertension.2002,39:87-92.
[1]Levy D,Garrison RJ,Savage DD,et al.Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.N Engl J Med.May 31 1990,322(22):1561-1566.
[2]Vakili BA,Okin PM,Devereux RB.Prognostic implications of left ventricular hypertrophy.Am Heart J.Mar 2001,141(3):334-341.
[3]Di Tullio MR,Zwas DR,Sacco RL,et al.Left ventricular mass and geometry and the risk of ischemic stroke.Stroke.Oct 2003,34(10):2380-2384.
[4]Verdecchia P,Porcellati C,Reboldi G,et al.Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.Circulation.Oct 23 2001,104(17):2039-2044.
[5]Schmieder RE,Martus R,Klingbeil A.Reversal of left ventricular hypertrophy in essential hypertension.A meta-analysis of randomized double-blind studies.Jama.May 15 1996,275(19):1507-1513.
[6]Galderisi M,Anderson KM,Wilson PW,et al.Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy(the Framingham Heart Study).Am J Cardiol.Jul 1 1991,68(1):85-89.
[7]Ganau A,Devereux RB,Pickering TG,et al.Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension.Circulation.Jan 1990,81(1):25-36.
[8]Post WS,Larson MG,Myers RH,et al.Heritability of left ventricular mass:the Framingham Heart Study.Hypertension.Nov 1997,30(5):1025-1028.
[9]Tanase H,Yamori Y,Hansen CT,et al.Heart size in inbred strains of rats.Part 1.Genetic determination of the development of cardiovascular enlargement in rats.Hypertension.Nov-Dec 1982,4(6):864-872.
[10]Huss JM,Kelly DP.Nuclear receptor signaling and cardiac energetics.Circ Res.2004;95:568-578
[11]Raij L.Nitric oxide in hypertension:relationship with renal injury and left ventricular hypertrophy.Hypertension 1998,31:189-193.
[12]Miyazaki H,Matsuoka H,Cooke JP,et al.Endogenous nitric oxide synthase inhibitor:a novel marker of atherosclerosis.Circulation.1999,99:1141-1146.
[13]Boger RH,Bode-Boger SM,Szuba A,et al.Asymmetric dimethylarginine(ADMA):a novel risk factor for endothelial dysfunction:its role in hypercholesterolemia.Circulation.1998,98:1842-1847.
[14]Stuhlinger MC,Oka RK,Graf EE,et al.Endothelial dysfunction induced by hyperhomocyst(e) inemia:role of asymmetric dimethylarginine.Circulation,2003,108:933-938.
[15]Boger RH,Bode-Boger SM,Thiele W,et al.Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.J Am Coll Cardiol.1998,32:1336-1344.
[16]Wang J,Sim AS,Wang XL,et al.Relations between plasma asymmetric dimethylarginine(ADMA) and risk factors for coronary disease.Atherosclerosis.2006,184:383-388.
[17]Lin KY,Ito A,Asagami T,et al.Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.Circulation.2002,106: 987-992.
[18]Goonasekera CD,Rees DD,Woolard P,et al.Nitric oxide synthase inhibitors and hypertension in children and adolescents.J Hypertens.1997,15:901-909.
[19]Usui M,Matsuoka H,Miyazaki H,et al.Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.Life Sci.1998,62:2425-2430.
[20]Zoccali C,Mallamaci F,Maas R,et al.Left ventricular hypertrophy,cardiac remodeling and asymmetric dimethylarginine(ADMA) in hemodialysis patients.Kidney Int 2002,62:339-345.
[21]Tran C,Leiper J,Vallance P.The DDAH/ADMA/NOS pathway.Atherosclerosis.2003,4s(Suppl):33-40.
[22]Leiper JM,Santa Maria J,Chubb A,et al.Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.Biochem J.1999,343:209-214.
[23]Jones LC,Tran CTL,Leiper JM,et al.Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.Biochem Biophys Res Commun.2003,310:836-843.
[24]Whitworth JA.2003 World Health Organization(WHO)/International Society of Hypertension(ISH) statement on management of hypertension.J Hypertens.Nov 2003,21(11):1983-1992.
[25]Tajik AJ,Seward JB,Hagler DJ,et al.Two-dimensional real-time ultrasonic imaging of the heart and great vessels.Mayo Clin Proc.1978,53:271-303.
[26]Sahn DJ,DeMaria A,Kisslo J,et al.Recommendations regarding quantitation in M-mode echocardiography:results of a survey of echocardiographic measurements.Circulation.1978,58:1072-1083.
[27]Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy finding.Am J Cardiol.1986,57:450-458.
[28]De Simone G,Devereux RB,Daniels SR,et al.Effect of growth on variability of left ventricular mass:assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk.J Am Coll Cardiol.1995,25:1056-1062.
[29]Ganau A,Devereux RB,Roman MJ,et al.Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.J Am Coll Cardiol.1992,19:1550-1558.
[30]Leadon SA,Cerutti PA.A rapid and mild procedure of the isolation of DNA from mammalian cells.Anal Biochem.1982,120:282-288.
[31]Committee E.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.Jul 1997,20(7):1183-1197.
[32]Cockcroft DW,Gauh MH.Prediction of creatinine clearance from serum creatinine.Nephron.1976,16:31-41.
[33]Kato N,Sugiyama T,Morita H,et al.Genetic analysis of the atrial natriuretic peptide gene in essential hypertension.Clin Sci.2000,98:251-258.
[34]Bubikat A,De Windt LJ,Zetsche B,et al.Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice.J Biol Chem.2005,280(22):21594-21599.
[35]Kempf T,Wollert KC.Nitric oxide and the enigma of cardiac hypertrophy.Bioessays.2004,6:608-615.
[36]MacAllister R,Parry H,Kimoto M,et al.Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.Br J Pharmacol.1996,119:1533-1540.
[37]Sydow K,Munzel T.ADMA and oxidative stress.Atheroscler Suppl.2003,4:41-51.
[38]Michael J,O'Dwyerl,Felicity Dempsey,et al.Septic shock is correlated with asymmetrical dimethyl arginine levels,which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene:a prospective observational study.Critical Care.2006,10:R139.
[1]Leiper J,Vallance P.Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.Cardiovasc Res.2003,43:542-548.
[2]Vallance P,Leiper J.Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.Arterioscler Thromb Vasc Biol.2004,24:1023-1030.
[3]Jia SJ,Jiang DJ,Hu CP,et al.Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells.Vascul Pharmacol.2006,44:143-148.
[4]Achan V,Broadhead M,Malaki M,et al.Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.Arterioscler Thromb Vasc Biol.2003,23:1455-1459.
[5]Dayoub H,Achan V,Adimoolam S,et al.Dimeth-ylarginine dimethylaminohydrolase regulates nitric oxide synthesis.Circulation.2003,108:3042-3047.
[6]Griendling KK,FitzGerald Ga.Oxidative stress and cardiovascular injury II.Animal and human studies.Circulation.2003,108:2034-2040.
[7]Deng X,Welch WJ,Wilcox CS.Renal vasoconstriction during inhibition of NO synthase:effects of dietary salt.Kidney Int.1994,46:639-646.
[8]Ortiz PA,Hong NJ,Garvin JL.NO decreases thick ascending limb chloride absorption by reducing Na~+-K~+-2Cl~-cotransporter activity.Am J Physiol Renal Physiol.2001,281:F819-F825.
[9]Stoos BA,Garcia NH,Garvin JL.Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct.J Am Soc Nephrol.1995,6:89-94.
[10]Salazar FJ,Alberola A,Pinilla JM,et al.Saltinduced increase in arterial pressure during nitric oxide synthesis inhibition.Hypertension.1993,22:49-55.
[11]Ogawa T,Kimoto M,Watanabe H,et al.Metabolism of NG,NGand N~G,N'~G-dimethylarginine in rats.Arch Biochem Biophys.1987,252:526-537.
[12]Vallance P,Leone A,Calver A,et al.Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.Lancet.1992,339:572-575.
[13]Kitiyakara C,Chabrashvili T,Jose P,et al.Effects of dietary salt intake on plasma arginine.Am J Physiol Regul Integr Comp Physiol.2001,280:R1069-R1075,.
[14]Wang D,Gill P,Chabrashvili T,et al.Isoform-specific regulation by NG,NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO.Circ Res.2007,101:627-635.
[15]Leiper J,Nandi M,Torondel B,et al.Disruption of methylarginine metabolism impairs vascular homeostasis.Nat Med.2007,13:198-203.
[16]Kakimoto Y,Akazawa S.Isolation and identification of N~G,N'~G-and NG,NG_-dimethylarginine,N-mono-,di-,and trimethyllysine,and glucosylgalactosyl-and galactosyl-hydroxylysine from human urine.J Biol Chem.1970,245:5751-5758.
[17]Ogawa T,Kimoto M,Sasaoka K.Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats.Biochem Biophys Res Commun.1987,148:671-677.
[18]Leiper JM,Santa Maria J,Chubb A,et al.Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.Biochem J.1999,343:209-214.
[19]Tojo A,Welch WJ,Bremer V,et al.Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney.Kidney Int.1997,52:1593-1601.
[20]Ogawa T,Kimoto M,Sasaoka K.Purification and properties of a new enzyme,NG,NG-dimethylarginine dimethylaminohydrolase,from rat kidney.J Biol Chem.1989,264:10205-10209.
[21]Knipp M,Charnock JM,Garner CD,et al.Structural and functional characterization of the Zn(II) site in dimethylargininase-1(DDAH-1) from bovine brain.Zn(II) release activates DDAH-1.J Biol Chem.2001,276:40449-40456.
[22]Birdsey GM,Leiper JM,Vallance P.Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line.Acta Physiol Scand.2000,168:73-79.
[23]Murray-Rust J,Leiper J,McAlister M,et al.Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase.Nat Struct Biol.2001,8:679-683.
[24]Knipp M.How to control NO production in cells:N~ω,N~ω-dimethyl-Larginine dimethylaminohydrolase as a novel drug target.Chembiochem.2006,7:879-889.
[25]Tran CT,Fox MF,Vallance P,et al.Chromosomal localization,gene structure,and expression pattern of DDAH1:comparison with DDAH2 and implications for evolutionary origins.Genomics.2000,68:101-105.
[26]Teerlink T.ADMA metabolism and clearance.Vasc Med.2005,10,Suppl 1: S73-S81.
[27]Gardiner SM,Kemp PA,Bennett T,et al.Regional and cardiac haemodynamic effects of NG,NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats.Br J Pharmacol.1993,110:1457-1464.
[28]Heitzer T,Yla-Herttuala S,Luoma J,et al.Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia.Role of oxidized LDL.Circulation.1996,93:1346-1353.
[29]0'Driscoll G,Green D,Maiorana A,et al.Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus.J Am Coll Cardiol.1999,33:1506-1511.
[30]O'Driscoll G,Green D,Rankin J,et al.Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus.J Clin Invest.1997,100:678-684.
[31]Tawakol A,Omland T.Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans.Circulation.1997,95:1119-1121.
[32]Achan V,Tran CT,Arrigoni F,et al.All transretinoic acid increases nitric oxide synthesis by endothelial cells.Circ Res.2002,90:764-769.
[33]Wakino S,Hayashi K,Tatematsu S,et al.Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.Hypertens Res.2005,28:255-262.
[34]Monsalve E,Oviedo PJ,Garcia-Perez MA,et al.Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells.Cardiovasc Res.2007,73:66-72.
[35]Tanaka M,Osanai T,Murakami R,et al.Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells:enhanced release of asymmetric dimethylarginine.J Hypertens.2006,24:489-497.
[36]Sorrenti V,Mazza F,Campisi A,et al.High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells.Curr Neurovasc Res.2006,3:49-54.
[37]Ueda S,Kato S,Matsuoka H,et al.Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine.Circ Res.2003,92:226-233.
[38]Ito A,Tsao PS,Adimoolam S,et al.Novel mechanism for endothelial dysfunction:dysregulation of dimethylarginine dimethylaminohydrolase.Circulation.1999,99:3092-3095.
[39]Stone EM,Schaljer TH,Bianchi H,et al.Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine:dimethylargininase and peptidylarginine deiminase.Biochemistry.2005,44:13744-13752.
[40]Jones LC,Tran CTL,Leiper JM,et al.Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.Biochem Biophys Res Commun.2003,310:836-843.
[41]Wang C,Xu D,Zhang L,Xie D,et al.Molecular dynamics and density functional studies of substrate binding and catalysis of arginine deiminase.J Phys Chem B.2007,111:3267-3273.
[42]Frey D,Braun O,Briand C,et al.Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase:a basis for the design of specific inhibitors.Structure.2006,14:901-911.
[43]Berger SL.The complex language of chromatin regulation during transcription.Nature.2007,447:407-412.
[44]Polotskaia A,Wang M,Patschan S,et al.Regulation of arginine methylation in endothelial cells:role in premature senescence and apoptosis.Cell Cycle.2007,6:2524-2530.
[45]Tomikawa J,Fukatsu K,Tanaka S,et al.DNA methylationdependent epigenetic regulation of dimethylarginine dimethylaminohydrolase 2 gene in trophoblast cell lineage.J Biol Chem.2006,281:12163-12169.
[46]Jones LC,Tran CTL,Leiper JM,et al.Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.Biochem Biophys Res Commun.2003,310:836-843.
[47]Valkonen VP,Tuomainen TP,Laaksonen R.DDAH gene and cardiovascular risk.Vasc Med.2005,10,Suppl 1:S45-S48.
[48]Ryan R,Thornton J,Duggan E,et al.Gene polymorphism and requirement for vasopressor infusion after cardiac surgery.Ann Thorac Surg.2006,82:895-901.
[49]Nijveldt RJ,Teerlink T,Siroen MPC,et al.The liver is an important organ in the metabolism of asymmetrical dimethylarginine(ADMA).Clin Nutr.2003,22:17-22.
[50]Nijveldt RJ,Teerlink T,van Guldener C,et al.Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia.Nephrol Dial Tranplant.2003,18:2542-2550.
[51]Bultink IE,Teerlink T,Heijst JA,et al.Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events,disease activity,and organ damage in patients with systemic lupus erythematosus.Ann Rheum Dis.2005,64:1362-1365.
[52]Konishi H,Sydow K,Cooke JP.Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury.J Am Coll Cardiol.2007,49:1099-1105.
[53]Lu CW,Xiong Y,He P.Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein.Nitric Oxide.2007,16:94-103.
[54]Achan V,Ho HK,Heeschen C,et al.ADMA regulates angiogenesis:genetic and metabolic evidence.Vasc Med.2005,10:7-14.
[55]Wojciak-Stothard B,Torondel B,Tsang LY,et al.The ADMA/DDAH pathway is a critical regulator of endothelial cell motility.J Cell Sci.2007,120:929-942.
[56]Smith CL,Birdsey GM,Anthony S,et al.Dimethylarginine dimethylaminohydrolase activity modulatedADMA levels VEGF expression and cell phenotype.Biochem Biophys Res Commun.2003,308:984-989.
[57]Patschan S,Li H,Brodsky S,et al.Probing lipid rafts with proximity imaging:actions of proatherogenic stimuli.Am J Physiol Heart Circ Physiol.2006,290:H2210-H2219.
[58]Knipp M,Vasak M.A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline.Anal Biochem.2000,286:257-264.
[59]MacAllister RJ,Parry H,Kimoto M,et al.Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.Br J Pharmacol.1996,119:1533-1540.
[60]Nonaka S,Tsunoda M,Aoyama C,et al.Determination of N,N-dimethyl-L-arginine in rat plasma and dimethylarginine dimethylaminohydrolase activity in rat kidney using a monolithic silica column.J Chromatogr B Analyt Technol Biomed Life Sci.2006,843:170-174.
[61]Maas R,Tan-Andreesen J,Schwedhelm E,et al.A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase(DDAH) activity in mouse tissue.J Chromatogr B Analyt Technol Biomed Life Sci.2007,851:220-228.
[62]Tain YL,Baylis C.Determination of dimethylarginine dimethylaminohydrolase activity in the kidney.Kidney Int.2007,72:886-886.
[63]Assreuy J,Cunha FQ,Liew FY,et al.Feedback inhibition of nitric oxide synthase activity by nitric oxide.Br J Pharmacol.1993,108:833-837.
[64]Leiper J,Murray-Rust J,McDonald N,et al.S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity:Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase.Proc Natl Acad Sci USA.2002,99:13527-13532.
[65]Gow AJ,Chen Q,Hess DT,et al.Basal and stimulated protein S-nitrosylation in multiple cell types and tissues.J Biol Chem.2002,277:9637-9640.
[66]Stuhlinger MC,Tsao PS,Her JH,et al.Homocysteine impairs the nitric oxide synthase pathway:Role of asymmetric dimethylarginine.Circulation.2001,104:2569-2575.
[67]Knipp M,Braun O,Gehrig PM,et al.Zn(Ⅱ)-free dimethylargininase-1(DDAH-1) is inhibited upon specific Cys-Snitrosylation.J Biol Chem.2003,278:3410-3416.
[68]Jiang JL,Zhang XH,Li NS,et al.Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase 1 and dimethylarginine dimethylaminohydrolase activity.Cardiovasc Drugs Then 2006,20:281-294.
[69]Tan B,Jiang DJ,Huang H,et al.Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.Vascul Pharmacol.2007,46:338-345.
[70]Eid HM,Lyberg T,Arnesen H,et al.Insulin and adiponectin inhibit the TNF-a-induced ADMA accumulation in human endothelial cells:the role of DDAH.Atherosclerosis.2007,194:e1-e8.
[71]Yin QF,Xiong Y.Pravastatin restores DDAH activity and endotheliumdependent relaxation of rat aorta after exposure to glycated protein.J Cardiovasc Pharmacol.2005,45:525-532.
[72]Holden DP,Cartwright JE,Nussey SS,et al.Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine.Circulation.2003,108:1575-1580.
[73]Yang TL,Chen MF,Luo BL,et al.Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity.Naunyn Schmiedebergs Arch Pharmacol.2005,371:401-407.
[74]Xin HY,Jiang DJ,Jia SJ,et al.Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells.Thromb Haemost.2007,97:830-838.
[75]Yin QF,Fu SH,He P,et al.Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein:effects of aminoguanidine.Atherosclerosis.2007,190:53-61.
[76]Scalera F,Kielstein JT,Martens-Lobenhoffer J,et al.Erythropoietin increases asymmetric dimethylarginine in endothelial cells:role of dimethylarginine dimethylaminohydrolase.J Am Soc Nephrol.2005,16:892-898.
[77]Schaefer CB,Ooi SK,Bestor TH,et al.High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells.Curr Neurovasc Res.2006,3:49-54.
[78]Stone EM,Costello AL,Tierney Weis M,et al.Cytomegalovirus infection impairs the nitric oxide synthase pathway:role of asymmetric dimethylarginine in transplant arteriosclerosis.Circulation.2004,109:500-505.
[79]Xia Y,Tsai A,Berka V,et al.Superoxide generation from endothelial nitric-oxide synthase.J Biol Chem.1998,273:25804-25808.
[80]Pou S,Pou WS,Bredt DS,et al.Generation of superoxide by purified brain nitric oxide synthase.J Biol Chem.1992,267:24173-24176.
[81]Xia Y,Zweier JL.Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages.Proc Natl Acad Sci USA.1997,94:6954-6958.
[82]Wells SM,Holian A.Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells.Am J Respir Cell Mol Biol.2007,36:520-528.
[83]Xia Y,Dawson VL,Dawson TM,et al.Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury.Proc Natl Acad Sci USA.1996,93:6770-6774.
[84]Boger RH,Bode-Boger SM,Tsao PS,et al.An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.J Am Coll Cardiol.2000,36:2287-2295.
[85]Baylis C.Arginine,arginine analogs and nitric oxide production in chronic kidney disease.Nat Clin Pract Nephrol.2006,2:209-220.
[86]Chen MF,Xie XM,Yang TL,et al.Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II.J Vasc Res.2007,44:391-402.
[87]Choi KC,Kim NH,An MR,et al.Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.Biochem Biophys Res Commun.2006,349:683-693.
[88]Wang J,Sim AS,Wang XL,et al.L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic(HepG2) cells.Cell Mol Life Sci.2006,63:2838-2846.
[89]Deng X,Welch WJ,Wilcox CS.Renal vasodilation with L-arginine:effects of dietary salt.Hypertension.1995,26:256-262.
[90]Joshi MS,Ferguson TB Jr,Johnson FK,et al.Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells.Proc Natl Acad Sci USA.2007,104:9982-9987.
[91]Vallance P,Bush HD,Mok BJ,et al.Inhibition of dimethylarginine dimethylaminohydrolase(DDAH) and arginine deiminase(ADI) by pentafluorophenyl(PFP) sulfonates.Chem Commun(Camb).2005,44:5563-5565.
[92]Rossiter S,Smith CL,Malaki M,et al.Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase.J Med Chem.2005,48:4670-4678.
[93]Hartzoulakis B,Rossiter S,Gill H,et al.Discovery of inhibitors of the pentein superfamily protein dimethylarginine dimethylaminohydrolase(DDAH),by virtual screening and hit analysis.Bioorg Med Chem Lett.2007,17:3953-3956.
[94]Smith CL,Anthony S,Hubank M,et al.Effects of ADMA upon gene expression:an insight into the pathophysiological significance of raised plasma ADMA.PLoS Med.2005,2:1031-1043.
[95]Hruska KA,Saab G,Chaudhary LR,et al.Kidney-bone,bone-kidney,and cell-cell communications in renal osteodystrophy.Semin Nephrol.2004,24:25-38.
[96]Herpin A,Cunningham C.Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes.FEBS J.2007,274:2977-2985.
[97]Kearns AE,Donohue MM,Sanyal B,et al.Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro.J Biol Chem.2001,276:42213-42218.
[98]Wang D,Wang W,Gill P,et al.DDAH-2 regulates endothelial function,eNOS expression and nitric oxide activity in rat mesenteric resistance vessels(Abstract).Proc AHA 61 st Annu High Blood Pressure Res Conf.2007,152:LB32.
[99]Cooke JP.NO and angiogenesis.Atheroscler.2003,Suppl 4:53-60.
[100]Babaei S,Teichert-Kuliszewska K,Monge JC,et al.Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor.Circ Res.1998,82:1007-1015.
[101]Papapetropoulos A,Desai KM,Rudic RD,et al.Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro.Am J Pathol.1997,150:1835-1844.
[102]Ziche M,Morbidelli L,Choudhuri R,et al.Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.J Clin Invest.1997,99:2625-2634.
[103]Hasegawa K,Wakino S,Tanaka T,et al.Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Spl transcription factor in endothelial cells.Arterioscler Thromb Vasc Biol.2006,26:1488-1494.
[104]Tokuo H,Yunoue S,Feng L,et al.Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of NG,NG-dimethylarginine dimethylaminohydrolase.FEBS Lett.2001,494:48-53.
[105]Leiper J,Vallance P.New tricks from an old dog:nitric oxideindependent effects of dimethylarginine dimethylaminohydrolase.Arterioscler Thromb Vasc Biol.2006,26:1419-1420.
[106]Zoccali C,Mallamaci F,Maas R,et al.Left ventricular hypertrophy,cardiac remodeling and asymmetric dimethylarginine(ADMA) in hemodialysis patients.Kidney Int.2002,62:339-345.
[107]Zoccali C.ADMA:a critical cardio-renal link in heart failure? Eur J Clin Invest.2003,33:361-362.
[108]Arrigoni FI,Vallance P,Haworth SG,et al.Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia.Circulation.2003,107:1195-1201.
[109]Wang D,Iversen J,Wilcox CS,et al.Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal polycystic kidney disease.Kidney Int.2003,64:1381-1388.
[110]CurgunIu A,Uzun H,Bavunoglu I,et al.Increased circulating concentrations of asymmetric dimethylarginine(ADMA) in white coat hypertension.J Hum Hypertens.2005,19:629-633.
[111]Ito A,Egashira K,Narishige T,et al.Reninangiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.Jpn Circ J.2001,65:775-778.
[112]Perticone F,Sciacqua A,Maio R,et al.Asymmetric dimethylarginine,L-arginine,and endothelial dysfunction in essential hypertension.J Am Coll Cardiol.2005,46:518-523.
[113]Surdacki A,Nowicki M,Sandmann J,et al.Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.J Cardiovasc Pharmacol.1999,33:652-658.
[114]Meinitzer A,Seelhorst U,Wellnitz B,et al.Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease(the Ludwigshafen Risk and Cardiovascular Health study).Clin Chem.2007,53:273-283.
[115]Paiva H,Laakso J,Kahonen M,et al.Asymmetric dimethylarginine and hemodynamic regulation in middle-aged men.Metabolism.2006,55:771-777.
[116]Schnabel R,Blankenberg S,Lubos E,et al.Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease:results from the AtheroGene Study.Circ Res.2005,97:e53-e59.
[117]Schulze F,Maas R,Freese R,et al.Determination of a reference value for NG,NG-dimethyl-L-arginine in 500 subjects.Eur J Clin Invest.2005,35:622-626.
[118]Aslam S,Santha T,Leone A,et al.Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.Kidney Int.2006,70:2109-2115.
[119]Chen JW,Hsu NW,Wu TC,et al.Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.Am J Cardiol.2002,90:974-982.
[120]Delles C,Schneider MP,John S,et al.Angiotensin converting enzyme inhibition and angiotensin II AT1 receptor blockade reduce the levels of asymmetrical NG,NG-dimethylarginine in human essential hypertension.Am J Hypertens.2002,15:590-593.
[121]Warnholtz A,Ostad MA,Heitzer T,et al.AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.Atherosclerosis.2007,194:439-445.
[122]Hasegawa K,Wakino S,Tatematsu S,et al.Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase 2.Circ Res.2007,101:e2-e10.
[123]Chen MF,Xie XM,Yang TL,et al.Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II.J Vasc Res.2007,44:391-402.
[124]Stone EM,Costello AL,Tierney DL,et al.Substrate-assisted cysteine deprotonation in the mechanism of dimethylargininase(DDAH) from Pseudomonas aeruginosa.Biochemistry.2006,45:5618-5630.
[125]Wang J,Sim AS,Wang XL,et al.Relations between plasma asymmetric dimethylarginine(ADMA) and risk factors for coronary disease.Atherosclerosis.2006,184:383-388.
[126]Miyazaki H,Matsuoka H,Cooke JP,et al.Endogenous nitric oxide synthase inhibitor:a novel marker of atherosclerosis.Circulation.1999,99:1141-1146.
[127]Boger RH,Bode-Boger SM,Thiele W,et al.Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.J Am Coll Cardiol.1998,32:1336-1344.
[128]Boger RH,Sydow K,Borlak T,et al.LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells.Circ Res.2000,87:99-105.
[129]Ito A,Tsao PS,Adimoolam S,et al.Novel mechanism for endothelial dysfunction:dysregulation of dimethylarginine dimethylaminohydrolase.Circulation.1999,99:3092-3095.
[130]Lundman P,Eriksson MJ,Stuhlinger MC,et al.Mild to moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine.J Am Coll Cardiol.2001,38:111-116.
[131]Zoccali C,Benedetto F,Maas R,et al.Asymmetric dimethylarginine,C-reactive protein,and carotid intima-media thickness in end-stage renal disease.J Am Soc Nephrol.2002,13:490-496.
[132]Lu R,Hu CP,Wu XP,et al.Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats.Comput Med.2003,52:224-228.
[133]Scuteri A,Stuehlinger MC,Cooke JP,et al.Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women.J Hypertens.2003,21:1339-1346.
[134]Wilcken DE,Wang J,Sim AS,et al.Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency:relevance of renal function.J Inherit Metab Dis.2006,29:30-37.
[135]Su Y,Han W,Giraldo C,et al.Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells.Am J Respir Cell Mol Biol.1998,19:819-825.
[136]Barbera JA,Peinado VI,Santos S,et al.Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers.Am J Respir Crit Care Med.2001,164:709-713.
[2]Vakili BA,Okin PM,Devereux RB.Prognostic implications of left ventricular hypertrophy.Am Heart J.Mar 2001,141(3):334-341.
[3]Di Tullio MR,Zwas DR,Sacco RL,et al.Left ventricular mass and geometry and the risk of ischemic stroke.Stroke.Oct 2003,34(10):2380-2384.
[4]Verdecchia P,Porcellati C,Reboldi G,et al.Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.Circulation.Oct 23 2001,104(17):2039-2044.
[5]Schmieder RE,Martus P,Klingbeil A.Reversal of left ventricular hypertrophy in essential hypertension.A meta-analysis of randomized double-blind studies.Jama.May 15 1996,275(19):1507-1513.
[6]Galderisi M,Anderson KM,Wilson PW,et al.Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy(the Framingham Heart Study).Am J Cardiol.Jul 1 1991,68(1):85-89.
[7]Ganau A,Devereux RB,Pickering TG,et al.Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension.Circulation.Jan 1990,81(1):25-36.
[8]Post WS,Larson MG,Myers RH,et al.Heritability of left ventricular mass:the Framingham Heart Study.Hypertension.Nov 1997,30(5):1025-1028.
[9]Tanase H,Yamori Y,Hansen CT,et al.Heart size in inbred strains of rats.Part 1.Genetic determination of the development of cardiovascular enlargement in rats.Hypertension.Nov-Dec 1982,4(6):864-872.
[10]Huss JM,Kelly DP.Nuclear receptor signaling and cardiac energetics.Circ Res.2004,95:568-578.
[1 l]F(?)rstermann U,Boissel JP,Kleinert H.Expressional control of the 'constitutive' isoforms of nitric oxide synthase(NOS I and NOS III).FASEB J.1998 Jul,12(10):773-790.
[12]F(?)rstermann U,Closs El,Pollock JS,et al.Nitric oxide synthase isozymes.Characterization,purification,molecular cloning,and functions.Hypertension.1994 Jun,23(6 Pt 2):1121-1131.
[13]F(?)rstermann U,Pollock JS,Schmidt HH,et al.Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells.Proc Natl Acad Sci U S A.1991 Mar 1,88(5):1788-1792.
[14]Sladek T,Gerova M,Znojil V,et al.Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase.Physiol Res 1996,45:335-338.
[15]Ichinose F,Bloch KD,Wu JC,et al.Pressure overload induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency.Am J Physiol Heart Circ Physiol.2004,286(3):H1070-H1075.
[16]Buys ES,Raher MJ,Blake SL,et al.Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload.Am J Physiol Heart Circ Physiol.2007,293:H620-H627.
[17]Janssens S,Pokreisz P,Schoonjans L,et al.Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.Circ.Res.2004,94:1256-1262.
[18]Stein B,Eschenhagen T,R(?)diger J,et al.Increased expression of constitutive nitric oxide synthase III,but not inducible nitric oxide synthase II,in human heart failure.J.Am.Coll.Cardiol.1998,32:1179-1186.
[19]Nakayama M,Yasue H,Yoshimura M,et al.-T786C mutation in the 5'-flanking region of the endothdial nitric oxide symhase gene is associated with myocardial infarction,especially without coronary organic stenosis.Am J Cardiol.2000,86(6):628-634.
[20]Pulkkinen A,Viitanen L,Kareinen A,et al.Intron 4 polymorphism of the endothelial nitric oxide synthase gene is associated with elevated blood pressure in type 2 diabetic patients with coronary heart disease.J Mol Med.2000,78(7):372-379.
[21]Btiyamoto Y,Saito Y,Kajiym N,et al.Hypertension.1998,32(1):3-8.
[22]Uwabo J,Soma M,Nakayama T,et al.Am J Hypertens.1998,11(1):125-128.
[23]Whitworth JA.2003 World Health Organization(WHO)/International Society of Hypertension(ISH) statement on management of hypertension.J Hypertens.Nov 2003,21(11):1983-1992.
[24]Tajik AJ,Seward JB,Hagler DJ,et al.Two-dimensional real-time ultrasonic imaging of the heart and great vessels.Mayo Clin Proc.1978,53:271-303.
[25]Sahn DJ,DeMaria A,Kisslo J,et al.Recommendations regarding quantitation in M-mode echocardiography:results of a survey of echocardiographic measurements. Circulation.1978,58:1072-1083.
[26]Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy finding.Am J Cardiol.1986,57:450-458.
[27]De Simone G,Devereux RB,Daniels SR,et al.Effect of growth on variability of left ventricular mass:assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk.J Am Coll Cardiol.1995,25:1056-1062.
[28]Ganau A,Devereux RB,Roman MJ,et al.Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.J Am Coll Cardiol.1992,19:1550-1558.
[29]Leadon SA,Cerutti PA.A rapid and mild procedure of the isolation of DNA from mammalian cells.Anal Biochem.1982,120:282-288.
[30]Committee E.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.Jul 1997,20(7):1183-1197.
[31]Cockcroft DW,Gauh MH.Prediction of creatinine clearance from serum creatinine.Nephron.1976,16:31-41.
[32]Kato N,Sugiyama T,Morita H,et al.Genetic analysis of the atrial natriuretic peptide gene in essential hypertension.Clin Sci.2000,98:251-258.
[33]Garcia-Cardena G,Martasek P,Masters BS,et al.Dissecting the interaction between nitric oxide synthase(NOS) and caveolin.Functional significance of the NOS caveolin binding domain in vivo.J.Biol.Chem.1997,272:25437-25440.
[34]Shaul PW,Anderson RG.Role of plasmalemmal caveolae in signal transduction.Am.J.Physiol.1998,275:L843-L851.
[35]Govers R,Rabelink TJ.Cellular regulation of endothelial nitric oxide synthase.Am.J.Physiol.2001,280:F193-F206.
[36]Nakayama M,Yasue H,Yoshimura M,et al.T-786＞C mutation in the 5'-flanking region of endothelial nitric oxide synthase gene is associated with coronary spasm.Circulation.1999,99:2864-2870.
[37]Wang XL,Sim AS,Wang MX,et al.Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity.FEBS Lett.2000,471:45-50.
[38]Tesauro M,Thompson WC,Rogliani P,et al.Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary disease:cleavage of proteins with aspartate vs.Glutamate at position 298.Proc Natl Acad Sci USA.2000,97:2832-2835.
[39]Ahmadi KR,Weale ME,Xue ZY,et al.A single-nucleotide polymorphism tagging set for human drug metabolism and transport.Nat.Genet.2005,37:84-89.
[40]Fairchild TA,Fulton D,Fontana JT,et al.Acidic hydrolysis as a mechanism for the cleavage of the glu(298) asp variant of human endothelial nitric-oxide synthase.J.Biol.Chem.2001,276:26674-26679.
[41]McDonald DM,Alp NJ,Channon KM.Functional comparison of the endothelial nitric oxide synthase glu298asp polymorphic variants in human endothelial cells.Pharmacogenetics.2004,14:831-839.
[42]Lapu-Bula R,Quarshie A,Lyn D,et al.The 894T allele of endothelial nitric oxide synthase gene is related to left ventricular mass in African Americans with high-normal blood pressure.J.Natl.Med.Assoc.2005,97:197-205.
[43]Minushkina LO,Zate(?)shchikov DA,ZateTshchikova AA,et al.NOS3 gene polymorphism and left ventricular hypertrophy in patients with essential hypertension.Kardiologiia.2002,42:30-34.
[44]01cay A,Ekmekci CG,Ozbek U,et al.Negative association of endothelial nitric oxide gene polymorphism with hypertension in Turkish patients:effect of eNOS polymorphism on left ventricular hypertrophy.Cardiovasc.Ultrasound.2006,4:33.
[1]Kannel WB.Prevalence and natural history of electrocardiographic left ventricular hypertrophy.Am J Med.1983,3:4-11.
[2]Lorell BH,Carabello BA.Left ventricular hypertrophy:pathogenesis,detection,and prognosis.Circulation.2000,102:470-479.
[3]Hunter J J,Chien KR.Signaling pathways for cardiac hypertrophy and failure.N Engl J Med.1999,341:1276-1283.
[4]Wollert KC,Drexler H.Regulation of cardiac remodeling by nitric oxide:focus on cardiac myocite hypertrophy and apoptosis.Heart Fail Rev.2002,7:317-325.
[5]Kempf T,Wollert KC.Nitric oxide and the enigma of cardiac hypertrophy.Bioessays.2004,6:608-615.
[6]Russell B,Motlagh D,Ashley WW.Form follows function:how muscle shape is regulated by work.J Appl Physiol.2000,88:1127-1132.
[7]Pereira FEL.Hipertrofia cardiaca:aspectos morfologicos e patogeneticos.In Vassale DV,Lima EG(eds).Contratilidade miocardica:aspectos basicos e clinicos.Sao Paulo:BYK,1993,p13-28.
[8]Ozaki M,Kawashima S,Yamashita T,Hirase T,Ohashi Y,Inoue N,et al.Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion.Circ J.2002,66:851-856.
[9]Morgan HE,Gordon EE,Kira Y,Chua BHL,Russo LA,Peterson CI,et al.Biochemical mechanisms of cardiac hypertrophy.Ann Rev Physiol.1987,49:533-543.
[10]Von Harsdorf R,Kang RE,Fullerton M,Woodcock EA.Myocardial stretch stimulates phosphatidyl-inositol turnover.Circ Res.1989,65:494-501.
[11]Sussman A,Mcculloch A,Borg TK.Dance band on the titanic:biomechanical signaling in cardiac hypertrophy.Circ Res.2002,91:888-898.
[12]Burridge K,Chrzanowska-Wodnicka M.Focal adhesions,contractility,and signaling.Annu Rev Cell Dev Biol.1996,12:463-519.
[13]Dash R,Schmidt AG,Pathak A,Gerst MJ,Biniakiewicz D,Kadambi VJ,et al.Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy.Cardiovasc Res.2003,57:704-714.
[14]Campos LA,Iliescu R,Fontes M,Schlegel WP,Bader M,Baltatu OC.Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.Am J Physiol Heart Circ Physiol.2006,291(5):H2371-2376.
[15]Shubeita HE,Martinson EA,Van Bilsen M,Chien KR,Brow JH.Transcriptional activation of the cardiac myosin light chain 2 and atrial natriuretic factor genes by protein kinase C in neonatal rat ventricular myocytes.Proc Natl Acad Sci USA.1992,89:1305-1309.
[I6]Lindpaintner K,Ganten D.The cardiac rennin-angiotensin system:an appraisal of present experimental and clinical evidence.Circ Res.1991,68(1):905-921.
[17]Shirai H,Takahashi K,Katada T,Inagami T.Mapping of G protein coupling sites of the angiotensin II type 1 receptor.Hypertension.1995,25:726-730.
[18]Bernstein KE,Ali MS,Sayeski PP,Semeniuk D,Marrero MB.New insights into the cellular signaling of seven transmembrane receptors:the role of tyrosine phosphorylation.Lab Invest.1998,78:3-7.
[19]Mukoyama M,Nakajima M,Horiuchi M,Sasamura H,Pratt RE,Dzau VJ.Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors.J Biol Chem.1993,268(33):24539-24542.
[20]Senbonmatsu T,Ichihara S,Price E,Gaffney FA,Inagami T.Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload.J Clin Invest.2000,106:R25-R29.
[21]Harada K,Komuro I,Shiojima I,Hayashi D,Kudoh S,Mizuno T,et al.Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice.Circulation.1998,97:1952-1959.
[22]Saltiel AR,Kahn CR.Insulin signalling and the regulation of glucose and lipid metabolism.Nature.2001,414:799-806.
[23]Velloso LA,Carvalho CR,Rojas FA,Folli F,Saad MJ.Insulin signalling in heart involves insulin receptor substrates-1 and-2,activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway.Cardiovasc Res.1998,40:96-102.
[24]Araujo EP,De Souza CT,Gasparetti AL,Ueno M,Boschero AC,Saad MJ,et al.Short-term in vivo inhibition of insulin receptor substrate-1 expression leads to insulin resistance,hyperinsulinemia,and increased adiposity.Endocrinology.2005,146:1428-1437.
[25]Zecchin HG,Carvalheira JBC,Saad MJA.Resistencia a insulina,diabetes e hipertensao:bases fisiopatologicas.Rev Bras Hipertens.2004,11(2):124-127.
[26]Gao F,Gao E,Yue TL,Ohlstein EH,Lopez BL,Christopher TA,et al.Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemiareperfusion:the roles of PI3-kinase,Akt,and endothelial nitric oxide synthase phosphorylation.Circulation.2002,105(12):1497-1502.
[27]Sykiotis GP,Papavassiliou AG.Serine phosphorylation of insulin receptor substrate-1:a novel target for the reversal of insulin resistance.Mol Endocrinol.2001,15:1864-1869.
[28]Brownsey RW,Boone AN,Allard MF.Actions of insulin on the mammalian heart:metabolism,pathology and biochemical mechanisms.Cardiovasc Res.1997,34:3-24.
[29]Samuelsson AM,Bollano E,Mobini R,Larsson BM,Omerovic E,Fu M,et al. Hyperinsulinemia:effect on cardiac mass/function,angiotensin II receptor expression,and insulin signaling pathways.Am J Physiol Heart Circ Physiol.2006,291:H787-H796.
[30]Lang D,Mosfer SI,Shakesby A,Donaldson F,Lewis MJ.Coronary microvascular endothelial cell redox state in left ventricular hypertrophy:the role of angiotensin II.Circ Res.2000,86:463-469.
[31]Sato K,Komaru T,Shioiri H,Takeda S,Takahashi K,Kanatsuka H,et al.Hypercholesterolemia impairs transduction of vasodilator signals derived from ischemic myocardium:myocardium-microvessel cross-talk.Arterioscler Thromb Vasc Biol.2004,24(11):2034-2039.
[32]Aikawa R,Nagai T,Tanaka M,Zou Y,Ishihara T,Takano H,et al.Reactive oxygen species in mechanical stress-induced cardiac hypertrophy.Biochem Biophys Res Commun.2001,289:901-907.
[33]Yao EH,Yu Y,Fukuda N.Oxidative stress on progenitor and stem cells in cardiovascular diseases.Curr Pharm Biotechnol.2006,7:101-108.
[34]Genda S,Miura T,Miki T,Ichikawa Y,Shimamoto K.K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia.J Am Coll Cardiol.2002,40(7):1339-1346.
[35]Lee TM,Lin MS,Chou TF,Tasai CH,Chang NC.Effect of pravastatin on left ventricular mass by activation of myocardial KATP channels in hypercholesterolemic rabbits.Atherosclerosis.2004,176:273-278.
[36]Lee TM,Lin SM,Chou TF,Chang NC.Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits.Am J Physiol Heart Circ Physiol.2005,288:H1352-H1358.
[37]Sugden P.H.Signaling pathways activated by vasoactive peptides in the cardiac myocytes and their role in the myocardial pathologies.J Card Fail.2002,8(6):S359-369.
[38]Vishnevetsky D,Kiyanista VA,Gandhi PJ.CD40 ligand:a novel target in the fight against cardiovascular disease.Ann Pharmacother.2004,38(9):1500-1508.
[39]Gelbmann CM,Leeb SN,Vogl D,Maendel M,Herfarth H,Scholmerich J,et al.Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts.Gut.2003,52(10):1448-1456.
[40]Vellaichamy E,Sommana NK,Pandey KN.Reduced cGMP signaling activates NF-kappaB in hypertrophied hearts of mice lacking natriuretic peptide receptor-A. Biochem Biophys Res Commun.2005,327(1):106-111.
[41]Hansson GK.Mechanisms of disease:inflammation,atherosclerosis,and coronary artery disease.N Engl J Med.2005,352:1685-1695.
[42]Peng J,Gurantz D,Tran V,Cowling RT,Greenberg BH.Tumor necrosis factor-alpha-induced ATI receptor upregulation enhances angiotensina II-mediated cardiac fibroblast responses that favor fibrosis.Circ Res.2002,91:1119-1126.
[43]Bubikat A,De Windt LJ,Zetsche B,Fabritz L,Sickler H,Eckardt D,et al.Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice.J Biol Chem.2005,280(22):21594-21599.
[44]Barouch LA,Cappola TP,Harrison RW,Crone JK,Rodriguez ER,Burnett AL,et al.Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice.J Mol Cell Cardiol.2003,35:637-644.
[45]Fiedler B,Wollert KC.Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NF AT cascade in cardiac myocytes.Cardiovasc Res.2004,63(3):450-457.
[46]Cheng TH,Shih NL,Chen SY,Lin JW,Chen YL,Chen CH,et al.Nitric oxide inhibits endothel in-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation.Mol Pharmacol.2005,68(4):1183-1192.
[47]Bush PK,Bartkova J,Strom CC,Wulf-Andersen L,Hinrichsen R,Christoffersen TE,et al.Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro.Cardiovasc Res.2002,56:64-75.
[48]Massion PB,Feron O,Dessy C,Balligand JL.Nitric oxide and cardiac function:ten years after,and continuing.Circ Res.2003,93(5):388-398.
[49]Wollert KC,Fiedler B,Gambaryan S,Smolenski A,Heineke J,Butt E,et al.Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes.Hypertension.2002,39:87-92.
[1]Levy D,Garrison RJ,Savage DD,et al.Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.N Engl J Med.May 31 1990,322(22):1561-1566.
[2]Vakili BA,Okin PM,Devereux RB.Prognostic implications of left ventricular hypertrophy.Am Heart J.Mar 2001,141(3):334-341.
[3]Di Tullio MR,Zwas DR,Sacco RL,et al.Left ventricular mass and geometry and the risk of ischemic stroke.Stroke.Oct 2003,34(10):2380-2384.
[4]Verdecchia P,Porcellati C,Reboldi G,et al.Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.Circulation.Oct 23 2001,104(17):2039-2044.
[5]Schmieder RE,Martus R,Klingbeil A.Reversal of left ventricular hypertrophy in essential hypertension.A meta-analysis of randomized double-blind studies.Jama.May 15 1996,275(19):1507-1513.
[6]Galderisi M,Anderson KM,Wilson PW,et al.Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy(the Framingham Heart Study).Am J Cardiol.Jul 1 1991,68(1):85-89.
[7]Ganau A,Devereux RB,Pickering TG,et al.Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension.Circulation.Jan 1990,81(1):25-36.
[8]Post WS,Larson MG,Myers RH,et al.Heritability of left ventricular mass:the Framingham Heart Study.Hypertension.Nov 1997,30(5):1025-1028.
[9]Tanase H,Yamori Y,Hansen CT,et al.Heart size in inbred strains of rats.Part 1.Genetic determination of the development of cardiovascular enlargement in rats.Hypertension.Nov-Dec 1982,4(6):864-872.
[10]Huss JM,Kelly DP.Nuclear receptor signaling and cardiac energetics.Circ Res.2004;95:568-578
[11]Raij L.Nitric oxide in hypertension:relationship with renal injury and left ventricular hypertrophy.Hypertension 1998,31:189-193.
[12]Miyazaki H,Matsuoka H,Cooke JP,et al.Endogenous nitric oxide synthase inhibitor:a novel marker of atherosclerosis.Circulation.1999,99:1141-1146.
[13]Boger RH,Bode-Boger SM,Szuba A,et al.Asymmetric dimethylarginine(ADMA):a novel risk factor for endothelial dysfunction:its role in hypercholesterolemia.Circulation.1998,98:1842-1847.
[14]Stuhlinger MC,Oka RK,Graf EE,et al.Endothelial dysfunction induced by hyperhomocyst(e) inemia:role of asymmetric dimethylarginine.Circulation,2003,108:933-938.
[15]Boger RH,Bode-Boger SM,Thiele W,et al.Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.J Am Coll Cardiol.1998,32:1336-1344.
[16]Wang J,Sim AS,Wang XL,et al.Relations between plasma asymmetric dimethylarginine(ADMA) and risk factors for coronary disease.Atherosclerosis.2006,184:383-388.
[17]Lin KY,Ito A,Asagami T,et al.Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.Circulation.2002,106: 987-992.
[18]Goonasekera CD,Rees DD,Woolard P,et al.Nitric oxide synthase inhibitors and hypertension in children and adolescents.J Hypertens.1997,15:901-909.
[19]Usui M,Matsuoka H,Miyazaki H,et al.Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.Life Sci.1998,62:2425-2430.
[20]Zoccali C,Mallamaci F,Maas R,et al.Left ventricular hypertrophy,cardiac remodeling and asymmetric dimethylarginine(ADMA) in hemodialysis patients.Kidney Int 2002,62:339-345.
[21]Tran C,Leiper J,Vallance P.The DDAH/ADMA/NOS pathway.Atherosclerosis.2003,4s(Suppl):33-40.
[22]Leiper JM,Santa Maria J,Chubb A,et al.Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.Biochem J.1999,343:209-214.
[23]Jones LC,Tran CTL,Leiper JM,et al.Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.Biochem Biophys Res Commun.2003,310:836-843.
[24]Whitworth JA.2003 World Health Organization(WHO)/International Society of Hypertension(ISH) statement on management of hypertension.J Hypertens.Nov 2003,21(11):1983-1992.
[25]Tajik AJ,Seward JB,Hagler DJ,et al.Two-dimensional real-time ultrasonic imaging of the heart and great vessels.Mayo Clin Proc.1978,53:271-303.
[26]Sahn DJ,DeMaria A,Kisslo J,et al.Recommendations regarding quantitation in M-mode echocardiography:results of a survey of echocardiographic measurements.Circulation.1978,58:1072-1083.
[27]Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy finding.Am J Cardiol.1986,57:450-458.
[28]De Simone G,Devereux RB,Daniels SR,et al.Effect of growth on variability of left ventricular mass:assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk.J Am Coll Cardiol.1995,25:1056-1062.
[29]Ganau A,Devereux RB,Roman MJ,et al.Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.J Am Coll Cardiol.1992,19:1550-1558.
[30]Leadon SA,Cerutti PA.A rapid and mild procedure of the isolation of DNA from mammalian cells.Anal Biochem.1982,120:282-288.
[31]Committee E.Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.Diabetes Care.Jul 1997,20(7):1183-1197.
[32]Cockcroft DW,Gauh MH.Prediction of creatinine clearance from serum creatinine.Nephron.1976,16:31-41.
[33]Kato N,Sugiyama T,Morita H,et al.Genetic analysis of the atrial natriuretic peptide gene in essential hypertension.Clin Sci.2000,98:251-258.
[34]Bubikat A,De Windt LJ,Zetsche B,et al.Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice.J Biol Chem.2005,280(22):21594-21599.
[35]Kempf T,Wollert KC.Nitric oxide and the enigma of cardiac hypertrophy.Bioessays.2004,6:608-615.
[36]MacAllister R,Parry H,Kimoto M,et al.Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.Br J Pharmacol.1996,119:1533-1540.
[37]Sydow K,Munzel T.ADMA and oxidative stress.Atheroscler Suppl.2003,4:41-51.
[38]Michael J,O'Dwyerl,Felicity Dempsey,et al.Septic shock is correlated with asymmetrical dimethyl arginine levels,which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene:a prospective observational study.Critical Care.2006,10:R139.
[1]Leiper J,Vallance P.Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.Cardiovasc Res.2003,43:542-548.
[2]Vallance P,Leiper J.Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.Arterioscler Thromb Vasc Biol.2004,24:1023-1030.
[3]Jia SJ,Jiang DJ,Hu CP,et al.Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells.Vascul Pharmacol.2006,44:143-148.
[4]Achan V,Broadhead M,Malaki M,et al.Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.Arterioscler Thromb Vasc Biol.2003,23:1455-1459.
[5]Dayoub H,Achan V,Adimoolam S,et al.Dimeth-ylarginine dimethylaminohydrolase regulates nitric oxide synthesis.Circulation.2003,108:3042-3047.
[6]Griendling KK,FitzGerald Ga.Oxidative stress and cardiovascular injury II.Animal and human studies.Circulation.2003,108:2034-2040.
[7]Deng X,Welch WJ,Wilcox CS.Renal vasoconstriction during inhibition of NO synthase:effects of dietary salt.Kidney Int.1994,46:639-646.
[8]Ortiz PA,Hong NJ,Garvin JL.NO decreases thick ascending limb chloride absorption by reducing Na~+-K~+-2Cl~-cotransporter activity.Am J Physiol Renal Physiol.2001,281:F819-F825.
[9]Stoos BA,Garcia NH,Garvin JL.Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct.J Am Soc Nephrol.1995,6:89-94.
[10]Salazar FJ,Alberola A,Pinilla JM,et al.Saltinduced increase in arterial pressure during nitric oxide synthesis inhibition.Hypertension.1993,22:49-55.
[11]Ogawa T,Kimoto M,Watanabe H,et al.Metabolism of NG,NGand N~G,N'~G-dimethylarginine in rats.Arch Biochem Biophys.1987,252:526-537.
[12]Vallance P,Leone A,Calver A,et al.Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.Lancet.1992,339:572-575.
[13]Kitiyakara C,Chabrashvili T,Jose P,et al.Effects of dietary salt intake on plasma arginine.Am J Physiol Regul Integr Comp Physiol.2001,280:R1069-R1075,.
[14]Wang D,Gill P,Chabrashvili T,et al.Isoform-specific regulation by NG,NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO.Circ Res.2007,101:627-635.
[15]Leiper J,Nandi M,Torondel B,et al.Disruption of methylarginine metabolism impairs vascular homeostasis.Nat Med.2007,13:198-203.
[16]Kakimoto Y,Akazawa S.Isolation and identification of N~G,N'~G-and NG,NG_-dimethylarginine,N-mono-,di-,and trimethyllysine,and glucosylgalactosyl-and galactosyl-hydroxylysine from human urine.J Biol Chem.1970,245:5751-5758.
[17]Ogawa T,Kimoto M,Sasaoka K.Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats.Biochem Biophys Res Commun.1987,148:671-677.
[18]Leiper JM,Santa Maria J,Chubb A,et al.Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases.Biochem J.1999,343:209-214.
[19]Tojo A,Welch WJ,Bremer V,et al.Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney.Kidney Int.1997,52:1593-1601.
[20]Ogawa T,Kimoto M,Sasaoka K.Purification and properties of a new enzyme,NG,NG-dimethylarginine dimethylaminohydrolase,from rat kidney.J Biol Chem.1989,264:10205-10209.
[21]Knipp M,Charnock JM,Garner CD,et al.Structural and functional characterization of the Zn(II) site in dimethylargininase-1(DDAH-1) from bovine brain.Zn(II) release activates DDAH-1.J Biol Chem.2001,276:40449-40456.
[22]Birdsey GM,Leiper JM,Vallance P.Intracellular localization of dimethylarginine dimethylaminohydrolase overexpressed in an endothelial cell line.Acta Physiol Scand.2000,168:73-79.
[23]Murray-Rust J,Leiper J,McAlister M,et al.Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase.Nat Struct Biol.2001,8:679-683.
[24]Knipp M.How to control NO production in cells:N~ω,N~ω-dimethyl-Larginine dimethylaminohydrolase as a novel drug target.Chembiochem.2006,7:879-889.
[25]Tran CT,Fox MF,Vallance P,et al.Chromosomal localization,gene structure,and expression pattern of DDAH1:comparison with DDAH2 and implications for evolutionary origins.Genomics.2000,68:101-105.
[26]Teerlink T.ADMA metabolism and clearance.Vasc Med.2005,10,Suppl 1: S73-S81.
[27]Gardiner SM,Kemp PA,Bennett T,et al.Regional and cardiac haemodynamic effects of NG,NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats.Br J Pharmacol.1993,110:1457-1464.
[28]Heitzer T,Yla-Herttuala S,Luoma J,et al.Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia.Role of oxidized LDL.Circulation.1996,93:1346-1353.
[29]0'Driscoll G,Green D,Maiorana A,et al.Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus.J Am Coll Cardiol.1999,33:1506-1511.
[30]O'Driscoll G,Green D,Rankin J,et al.Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus.J Clin Invest.1997,100:678-684.
[31]Tawakol A,Omland T.Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans.Circulation.1997,95:1119-1121.
[32]Achan V,Tran CT,Arrigoni F,et al.All transretinoic acid increases nitric oxide synthesis by endothelial cells.Circ Res.2002,90:764-769.
[33]Wakino S,Hayashi K,Tatematsu S,et al.Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.Hypertens Res.2005,28:255-262.
[34]Monsalve E,Oviedo PJ,Garcia-Perez MA,et al.Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells.Cardiovasc Res.2007,73:66-72.
[35]Tanaka M,Osanai T,Murakami R,et al.Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells:enhanced release of asymmetric dimethylarginine.J Hypertens.2006,24:489-497.
[36]Sorrenti V,Mazza F,Campisi A,et al.High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells.Curr Neurovasc Res.2006,3:49-54.
[37]Ueda S,Kato S,Matsuoka H,et al.Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine.Circ Res.2003,92:226-233.
[38]Ito A,Tsao PS,Adimoolam S,et al.Novel mechanism for endothelial dysfunction:dysregulation of dimethylarginine dimethylaminohydrolase.Circulation.1999,99:3092-3095.
[39]Stone EM,Schaljer TH,Bianchi H,et al.Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine:dimethylargininase and peptidylarginine deiminase.Biochemistry.2005,44:13744-13752.
[40]Jones LC,Tran CTL,Leiper JM,et al.Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.Biochem Biophys Res Commun.2003,310:836-843.
[41]Wang C,Xu D,Zhang L,Xie D,et al.Molecular dynamics and density functional studies of substrate binding and catalysis of arginine deiminase.J Phys Chem B.2007,111:3267-3273.
[42]Frey D,Braun O,Briand C,et al.Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase:a basis for the design of specific inhibitors.Structure.2006,14:901-911.
[43]Berger SL.The complex language of chromatin regulation during transcription.Nature.2007,447:407-412.
[44]Polotskaia A,Wang M,Patschan S,et al.Regulation of arginine methylation in endothelial cells:role in premature senescence and apoptosis.Cell Cycle.2007,6:2524-2530.
[45]Tomikawa J,Fukatsu K,Tanaka S,et al.DNA methylationdependent epigenetic regulation of dimethylarginine dimethylaminohydrolase 2 gene in trophoblast cell lineage.J Biol Chem.2006,281:12163-12169.
[46]Jones LC,Tran CTL,Leiper JM,et al.Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells.Biochem Biophys Res Commun.2003,310:836-843.
[47]Valkonen VP,Tuomainen TP,Laaksonen R.DDAH gene and cardiovascular risk.Vasc Med.2005,10,Suppl 1:S45-S48.
[48]Ryan R,Thornton J,Duggan E,et al.Gene polymorphism and requirement for vasopressor infusion after cardiac surgery.Ann Thorac Surg.2006,82:895-901.
[49]Nijveldt RJ,Teerlink T,Siroen MPC,et al.The liver is an important organ in the metabolism of asymmetrical dimethylarginine(ADMA).Clin Nutr.2003,22:17-22.
[50]Nijveldt RJ,Teerlink T,van Guldener C,et al.Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia.Nephrol Dial Tranplant.2003,18:2542-2550.
[51]Bultink IE,Teerlink T,Heijst JA,et al.Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events,disease activity,and organ damage in patients with systemic lupus erythematosus.Ann Rheum Dis.2005,64:1362-1365.
[52]Konishi H,Sydow K,Cooke JP.Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury.J Am Coll Cardiol.2007,49:1099-1105.
[53]Lu CW,Xiong Y,He P.Dimethylarginine dimethylaminohydrolase-2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein.Nitric Oxide.2007,16:94-103.
[54]Achan V,Ho HK,Heeschen C,et al.ADMA regulates angiogenesis:genetic and metabolic evidence.Vasc Med.2005,10:7-14.
[55]Wojciak-Stothard B,Torondel B,Tsang LY,et al.The ADMA/DDAH pathway is a critical regulator of endothelial cell motility.J Cell Sci.2007,120:929-942.
[56]Smith CL,Birdsey GM,Anthony S,et al.Dimethylarginine dimethylaminohydrolase activity modulatedADMA levels VEGF expression and cell phenotype.Biochem Biophys Res Commun.2003,308:984-989.
[57]Patschan S,Li H,Brodsky S,et al.Probing lipid rafts with proximity imaging:actions of proatherogenic stimuli.Am J Physiol Heart Circ Physiol.2006,290:H2210-H2219.
[58]Knipp M,Vasak M.A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline.Anal Biochem.2000,286:257-264.
[59]MacAllister RJ,Parry H,Kimoto M,et al.Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase.Br J Pharmacol.1996,119:1533-1540.
[60]Nonaka S,Tsunoda M,Aoyama C,et al.Determination of N,N-dimethyl-L-arginine in rat plasma and dimethylarginine dimethylaminohydrolase activity in rat kidney using a monolithic silica column.J Chromatogr B Analyt Technol Biomed Life Sci.2006,843:170-174.
[61]Maas R,Tan-Andreesen J,Schwedhelm E,et al.A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase(DDAH) activity in mouse tissue.J Chromatogr B Analyt Technol Biomed Life Sci.2007,851:220-228.
[62]Tain YL,Baylis C.Determination of dimethylarginine dimethylaminohydrolase activity in the kidney.Kidney Int.2007,72:886-886.
[63]Assreuy J,Cunha FQ,Liew FY,et al.Feedback inhibition of nitric oxide synthase activity by nitric oxide.Br J Pharmacol.1993,108:833-837.
[64]Leiper J,Murray-Rust J,McDonald N,et al.S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity:Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase.Proc Natl Acad Sci USA.2002,99:13527-13532.
[65]Gow AJ,Chen Q,Hess DT,et al.Basal and stimulated protein S-nitrosylation in multiple cell types and tissues.J Biol Chem.2002,277:9637-9640.
[66]Stuhlinger MC,Tsao PS,Her JH,et al.Homocysteine impairs the nitric oxide synthase pathway:Role of asymmetric dimethylarginine.Circulation.2001,104:2569-2575.
[67]Knipp M,Braun O,Gehrig PM,et al.Zn(Ⅱ)-free dimethylargininase-1(DDAH-1) is inhibited upon specific Cys-Snitrosylation.J Biol Chem.2003,278:3410-3416.
[68]Jiang JL,Zhang XH,Li NS,et al.Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase 1 and dimethylarginine dimethylaminohydrolase activity.Cardiovasc Drugs Then 2006,20:281-294.
[69]Tan B,Jiang DJ,Huang H,et al.Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.Vascul Pharmacol.2007,46:338-345.
[70]Eid HM,Lyberg T,Arnesen H,et al.Insulin and adiponectin inhibit the TNF-a-induced ADMA accumulation in human endothelial cells:the role of DDAH.Atherosclerosis.2007,194:e1-e8.
[71]Yin QF,Xiong Y.Pravastatin restores DDAH activity and endotheliumdependent relaxation of rat aorta after exposure to glycated protein.J Cardiovasc Pharmacol.2005,45:525-532.
[72]Holden DP,Cartwright JE,Nussey SS,et al.Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine.Circulation.2003,108:1575-1580.
[73]Yang TL,Chen MF,Luo BL,et al.Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity.Naunyn Schmiedebergs Arch Pharmacol.2005,371:401-407.
[74]Xin HY,Jiang DJ,Jia SJ,et al.Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells.Thromb Haemost.2007,97:830-838.
[75]Yin QF,Fu SH,He P,et al.Dimethylarginine dimethylaminohydrolase inhibition and asymmetric dimethylarginine accumulation contribute to endothelial dysfunction in rats exposed to glycosylated protein:effects of aminoguanidine.Atherosclerosis.2007,190:53-61.
[76]Scalera F,Kielstein JT,Martens-Lobenhoffer J,et al.Erythropoietin increases asymmetric dimethylarginine in endothelial cells:role of dimethylarginine dimethylaminohydrolase.J Am Soc Nephrol.2005,16:892-898.
[77]Schaefer CB,Ooi SK,Bestor TH,et al.High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells.Curr Neurovasc Res.2006,3:49-54.
[78]Stone EM,Costello AL,Tierney Weis M,et al.Cytomegalovirus infection impairs the nitric oxide synthase pathway:role of asymmetric dimethylarginine in transplant arteriosclerosis.Circulation.2004,109:500-505.
[79]Xia Y,Tsai A,Berka V,et al.Superoxide generation from endothelial nitric-oxide synthase.J Biol Chem.1998,273:25804-25808.
[80]Pou S,Pou WS,Bredt DS,et al.Generation of superoxide by purified brain nitric oxide synthase.J Biol Chem.1992,267:24173-24176.
[81]Xia Y,Zweier JL.Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages.Proc Natl Acad Sci USA.1997,94:6954-6958.
[82]Wells SM,Holian A.Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells.Am J Respir Cell Mol Biol.2007,36:520-528.
[83]Xia Y,Dawson VL,Dawson TM,et al.Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury.Proc Natl Acad Sci USA.1996,93:6770-6774.
[84]Boger RH,Bode-Boger SM,Tsao PS,et al.An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes.J Am Coll Cardiol.2000,36:2287-2295.
[85]Baylis C.Arginine,arginine analogs and nitric oxide production in chronic kidney disease.Nat Clin Pract Nephrol.2006,2:209-220.
[86]Chen MF,Xie XM,Yang TL,et al.Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II.J Vasc Res.2007,44:391-402.
[87]Choi KC,Kim NH,An MR,et al.Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.Biochem Biophys Res Commun.2006,349:683-693.
[88]Wang J,Sim AS,Wang XL,et al.L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic(HepG2) cells.Cell Mol Life Sci.2006,63:2838-2846.
[89]Deng X,Welch WJ,Wilcox CS.Renal vasodilation with L-arginine:effects of dietary salt.Hypertension.1995,26:256-262.
[90]Joshi MS,Ferguson TB Jr,Johnson FK,et al.Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells.Proc Natl Acad Sci USA.2007,104:9982-9987.
[91]Vallance P,Bush HD,Mok BJ,et al.Inhibition of dimethylarginine dimethylaminohydrolase(DDAH) and arginine deiminase(ADI) by pentafluorophenyl(PFP) sulfonates.Chem Commun(Camb).2005,44:5563-5565.
[92]Rossiter S,Smith CL,Malaki M,et al.Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase.J Med Chem.2005,48:4670-4678.
[93]Hartzoulakis B,Rossiter S,Gill H,et al.Discovery of inhibitors of the pentein superfamily protein dimethylarginine dimethylaminohydrolase(DDAH),by virtual screening and hit analysis.Bioorg Med Chem Lett.2007,17:3953-3956.
[94]Smith CL,Anthony S,Hubank M,et al.Effects of ADMA upon gene expression:an insight into the pathophysiological significance of raised plasma ADMA.PLoS Med.2005,2:1031-1043.
[95]Hruska KA,Saab G,Chaudhary LR,et al.Kidney-bone,bone-kidney,and cell-cell communications in renal osteodystrophy.Semin Nephrol.2004,24:25-38.
[96]Herpin A,Cunningham C.Cross-talk between the bone morphogenetic protein pathway and other major signaling pathways results in tightly regulated cell-specific outcomes.FEBS J.2007,274:2977-2985.
[97]Kearns AE,Donohue MM,Sanyal B,et al.Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro.J Biol Chem.2001,276:42213-42218.
[98]Wang D,Wang W,Gill P,et al.DDAH-2 regulates endothelial function,eNOS expression and nitric oxide activity in rat mesenteric resistance vessels(Abstract).Proc AHA 61 st Annu High Blood Pressure Res Conf.2007,152:LB32.
[99]Cooke JP.NO and angiogenesis.Atheroscler.2003,Suppl 4:53-60.
[100]Babaei S,Teichert-Kuliszewska K,Monge JC,et al.Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor.Circ Res.1998,82:1007-1015.
[101]Papapetropoulos A,Desai KM,Rudic RD,et al.Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro.Am J Pathol.1997,150:1835-1844.
[102]Ziche M,Morbidelli L,Choudhuri R,et al.Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.J Clin Invest.1997,99:2625-2634.
[103]Hasegawa K,Wakino S,Tanaka T,et al.Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Spl transcription factor in endothelial cells.Arterioscler Thromb Vasc Biol.2006,26:1488-1494.
[104]Tokuo H,Yunoue S,Feng L,et al.Phosphorylation of neurofibromin by cAMP-dependent protein kinase is regulated via a cellular association of NG,NG-dimethylarginine dimethylaminohydrolase.FEBS Lett.2001,494:48-53.
[105]Leiper J,Vallance P.New tricks from an old dog:nitric oxideindependent effects of dimethylarginine dimethylaminohydrolase.Arterioscler Thromb Vasc Biol.2006,26:1419-1420.
[106]Zoccali C,Mallamaci F,Maas R,et al.Left ventricular hypertrophy,cardiac remodeling and asymmetric dimethylarginine(ADMA) in hemodialysis patients.Kidney Int.2002,62:339-345.
[107]Zoccali C.ADMA:a critical cardio-renal link in heart failure? Eur J Clin Invest.2003,33:361-362.
[108]Arrigoni FI,Vallance P,Haworth SG,et al.Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia.Circulation.2003,107:1195-1201.
[109]Wang D,Iversen J,Wilcox CS,et al.Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal polycystic kidney disease.Kidney Int.2003,64:1381-1388.
[110]CurgunIu A,Uzun H,Bavunoglu I,et al.Increased circulating concentrations of asymmetric dimethylarginine(ADMA) in white coat hypertension.J Hum Hypertens.2005,19:629-633.
[111]Ito A,Egashira K,Narishige T,et al.Reninangiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.Jpn Circ J.2001,65:775-778.
[112]Perticone F,Sciacqua A,Maio R,et al.Asymmetric dimethylarginine,L-arginine,and endothelial dysfunction in essential hypertension.J Am Coll Cardiol.2005,46:518-523.
[113]Surdacki A,Nowicki M,Sandmann J,et al.Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension.J Cardiovasc Pharmacol.1999,33:652-658.
[114]Meinitzer A,Seelhorst U,Wellnitz B,et al.Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease(the Ludwigshafen Risk and Cardiovascular Health study).Clin Chem.2007,53:273-283.
[115]Paiva H,Laakso J,Kahonen M,et al.Asymmetric dimethylarginine and hemodynamic regulation in middle-aged men.Metabolism.2006,55:771-777.
[116]Schnabel R,Blankenberg S,Lubos E,et al.Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease:results from the AtheroGene Study.Circ Res.2005,97:e53-e59.
[117]Schulze F,Maas R,Freese R,et al.Determination of a reference value for NG,NG-dimethyl-L-arginine in 500 subjects.Eur J Clin Invest.2005,35:622-626.
[118]Aslam S,Santha T,Leone A,et al.Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.Kidney Int.2006,70:2109-2115.
[119]Chen JW,Hsu NW,Wu TC,et al.Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.Am J Cardiol.2002,90:974-982.
[120]Delles C,Schneider MP,John S,et al.Angiotensin converting enzyme inhibition and angiotensin II AT1 receptor blockade reduce the levels of asymmetrical NG,NG-dimethylarginine in human essential hypertension.Am J Hypertens.2002,15:590-593.
[121]Warnholtz A,Ostad MA,Heitzer T,et al.AT1-receptor blockade with irbesartan improves peripheral but not coronary endothelial dysfunction in patients with stable coronary artery disease.Atherosclerosis.2007,194:439-445.
[122]Hasegawa K,Wakino S,Tatematsu S,et al.Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase 2.Circ Res.2007,101:e2-e10.
[123]Chen MF,Xie XM,Yang TL,et al.Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II.J Vasc Res.2007,44:391-402.
[124]Stone EM,Costello AL,Tierney DL,et al.Substrate-assisted cysteine deprotonation in the mechanism of dimethylargininase(DDAH) from Pseudomonas aeruginosa.Biochemistry.2006,45:5618-5630.
[125]Wang J,Sim AS,Wang XL,et al.Relations between plasma asymmetric dimethylarginine(ADMA) and risk factors for coronary disease.Atherosclerosis.2006,184:383-388.
[126]Miyazaki H,Matsuoka H,Cooke JP,et al.Endogenous nitric oxide synthase inhibitor:a novel marker of atherosclerosis.Circulation.1999,99:1141-1146.
[127]Boger RH,Bode-Boger SM,Thiele W,et al.Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.J Am Coll Cardiol.1998,32:1336-1344.
[128]Boger RH,Sydow K,Borlak T,et al.LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells.Circ Res.2000,87:99-105.
[129]Ito A,Tsao PS,Adimoolam S,et al.Novel mechanism for endothelial dysfunction:dysregulation of dimethylarginine dimethylaminohydrolase.Circulation.1999,99:3092-3095.
[130]Lundman P,Eriksson MJ,Stuhlinger MC,et al.Mild to moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine.J Am Coll Cardiol.2001,38:111-116.
[131]Zoccali C,Benedetto F,Maas R,et al.Asymmetric dimethylarginine,C-reactive protein,and carotid intima-media thickness in end-stage renal disease.J Am Soc Nephrol.2002,13:490-496.
[132]Lu R,Hu CP,Wu XP,et al.Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats.Comput Med.2003,52:224-228.
[133]Scuteri A,Stuehlinger MC,Cooke JP,et al.Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women.J Hypertens.2003,21:1339-1346.
[134]Wilcken DE,Wang J,Sim AS,et al.Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency:relevance of renal function.J Inherit Metab Dis.2006,29:30-37.
[135]Su Y,Han W,Giraldo C,et al.Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells.Am J Respir Cell Mol Biol.1998,19:819-825.
[136]Barbera JA,Peinado VI,Santos S,et al.Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers.Am J Respir Crit Care Med.2001,164:709-713.